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ABSTRACT
Smiley, Shelby B. M.S.B.M.E., Purdue University, May 2020. Targetable Multi-drug
Nanoparticles for Treatment of Glioblastoma with Neuroimaging Assessment.
Major Professor: Michael C. Veronesi.
Glioblastoma (GBM) is a deadly, malignant brain tumor with a poor long-term
prognosis. The current median survival is approximately fifteen to seventeen months
with the standard of care therapy which includes surgery, radiation, and chemother-
apy. An important factor contributing to recurrence of GBM is high resistance of
GBM cancer stem cells (CSCs), for which a systemically delivered single drug ap-
proach will be unlikely to produce a viable cure. Therefore, multi-drug therapies
are needed. Currently, only temozolomide (TMZ), which is a DNA alkylator, affects
overall survival in GBM patients. CSCs regenerate rapidly and over-express a methyl
transferase which overrides the DNA-alkylating mechanism of TMZ, leading to drug
resistance. Idasanutlin (RG7388, R05503781) is a potent, selective MDM2 antago-
nist that additively kills GBM CSCs when combined with TMZ. By harnessing the
strengths of nanotechnology, therapy can be combined with diagnostics in a truly ther-
anostic manner for enhancing personalized medicine against GBM. The goal of this
thesis was to develop a multi-drug therapy using multi-functional nanoparticles (NPs)
that preferentially target the GBM CSC subpopulation and provide in vivo preclin-
ical imaging capability. Polymer-micellar NPs composed of poly(styrene-b-ethylene
oxide) (PS-b-PEO) and poly(lactic-co-glycolic) acid (PLGA) were developed investi-
gating both single and double emulsion fabrication techniques as well as combinations
of TMZ and RG7388. The NPs were covalently bound to a 15 base-pair CD133 ap-
tamer in order to target a specific epitope on the CD133 antigen expressed on the
surface of GBM CSC subpopulation. For theranostic functionality, the NPs were
xvii
also labelled with a positron emission tomography (PET) radiotracer, zirconium-89
(89Zr). The NPs maintained a small size of less than 100 nm, a relatively neutral
charge and exhibited the ability to produce a cytotoxic effect on CSCs. There was a
slight increase in killing with the aptamer-bound NPs compared to those without a
targeting agent. This work has provided a potentially therapeutic option for GBM
specific for CSC targeting and future in vivo biodistribution studies.
11. INTRODUCTION
1.1 Glioblastoma overview
Gliomas are a group of primary, intrinsic brain tumors associated with limited
therapy options and a poor long-term outcome. Glioblastoma (GBM) is the most
malignant of the gliomas [1]. Affecting five to eight people per 100,000, GBM is
one of the most common brain tumors [2] [3]. GBM is resistant to therapy largely
because of an infiltrative nature and large genetic heterogeneity including multiple
mutations. In addition, recurrence is contributed by a self-renewing population of
cancer stem cells (CSCs) [4]. Development of new GBM therapies is an important
area of research given the lack of progress for the past fifteen years and because of
the profound impact of the disease on patients and society [1].
GBM affects approximately 14,000 people per year in the United States with a
median age of sixty-four years old [3] [5]. GBM affects men slightly more than women
according to the National Database of Central Brain Tumor Registry of the United
States (CBTRUS) [6]. A study published in 2018 from the National Cancer Institute’s
Surveillance Epidemiology and End Results (SEER) determined that out of the 3,473
patients with first time diagnosis of GBM, 83.2% were White non-Hispanic [7]. It
was also concluded that there was no statistical difference between the racial groups
tested and three-year overall survival time [7].
Like many cancers, GBM results in high cost for the patient and the physicians
and researchers working to treat the disease. Current treatments involve expensive
technology and frequent hospital visits for the patient. The direct cost for a patient
with GBM is estimated to be approximately $8,500 a month [8]. However, the total
GBM market cost distributed equally across the United States, Europe, Asia, and
2the rest of the world was approximately $465 million in 2016 and is expected to reach
$1 billion in 2025 [8].
The presenting symptoms for GBM are relatively nonspecific and are often mis-
diagnosed initially. Severity and presence of symptoms correlate with the size of
the tumor, location of the tumor, and whether eloquent areas of the brain are in-
volved [3]. The most common presentation of a GBM is the presence of a focal,
unilateral headache in about 50% of patients. [9]. Other presenting symptoms may in-
clude cognitive difficulties, ataxia, dizziness, and/or visual disturbance [10]. Seizures
are another common presentation often presenting earlier on in the disease progres-
sion [11].
Once clinical exam findings suggest a central nervous system abnormality, includ-
ing suspicion of a brain tumor, the primary initial workup includes contrast enhanced
magnetic resonance imaging (MRI) of the brain. MRI is comprised of over 1,000
images and permits information such as tumor location, size, affect on normal struc-
tures and extent of associated edema. The average size of a GBM at diagnosis is
approximately four-centimeters often indicating an advanced, incurable state once
that large [10]. Most of the tumors diagnosed are located in the brain rather than
the spinal cord and can occur in any location of the brain although they tend to in-
volve the cerebral hemispheres including the frontal lobe (25%), temporal lobe (20%),
parietal lobe (13%), and occipital lobe (3%) [3]. In addition to MRI, computed tomog-
raphy (CT) may be used as a diagnostic tool to indicate a possible brain tumor [3].
However, CT lacks the high tissue contrast needed for complete characterization.
On histopathalogic diagnosis, specific markers are associated with the various cell
types within a single glioma. Normal brain cells include neurons, glia, oligodendro-
cytes and immune cells, such as microglia. Glial cells provide essential nutrients and
a supportive environment for the neuron. GBM is thought to arise from precursors
to neurons and glia. Since GBM tumors are comprised of a heterogeneous number
of cell types, clinicians look at a variety of markers during a biopsy for definitive
diagnosis. For normal astrocytes, the most specific marker is the glial fibrillary acidic
3protein (GFAP) [10]. Loss of the GFAP is a marker of increased malignancy of the
tumor which aids in tumor grading. The World Health Organization (WHO) grades
tumors from I-IV based on various histologic parameters [10]. GBM is a grade IV
tumor, which is the most malignant tumor type, and has the highest degree of GFAP
loss. Cell irregularity is due to polymorphism (genetic variation within a popula-
tion), anaplasia (poor cellular differentiation), and anisokaryosis (larger than normal
variation). A biopsy of the tumor can also provide additional morphologic informa-
tion such as calcification, necrosis, and microcystic change [12] [13]. Other important
markers involved in treating GBM include isocitrate dehydrogenase (IDH) and O6-
methylguanine methyltransferase (MGMT). Briefly, the presence of a mutated IDH
corresponds to a longer survival time. In addition, it is typically found that patients
will have better prognosis when the MGMT promoter is methylated [14]. These will
be discussed later in further detail. Despite all that is known about the histology of
gliomas, there is still often no clear consensus amongst pathologists for adult glioma
diagnosis [15].
Cancer stem cells (CSCs) are believed to be an important contributing factor
in tumor recurrence. CSCs are thought to originate from within the subventricular
zone, which is located next to the ventricles of the brain. Glioma CSCs with certain
driver mutations may be the cells from which GBM originates. These special mutated
stem cells migrate away from the subventricular zones into the deeper brain regions
and mutate further, leading to the development of a glioma [16]. CSCs create an
extracellular tumor microenvironment that promotes GBM growth and maintains
the aggressiveness of the tumor [17]. Over time, these cells can help the tumor adapt
to conditions such as high lactic acidosis and hypoxia [17].
CSCs express several proteins that indicate stemness. For instance, CD133 (also
known as AC133 and prominin-1) is a 97 kDa transmembrane glycoprotein whose
function is not well known [18]. However, due to its typical location in plasma mem-
brane protrusions and microvilli, it is thought to be involved in membrane organi-
zation [18]. CD133 is an important biomarker used to identify the CSC population
4Fig. 1.1 Stem Cell Marker Profile. This figure represents data provided
by Celprogen on the CSC markers used during their quality analysis. On
the left shows the fluorescence achieved from selecting for CD133 while
the right shows the fluorescence achieved when selecting for CD44.
within various tumor types. Data provided by Celprogen analyzed CSCs based on
their presence of the CD133 marker alongside CD44 using flow cytommetry (Figure
1.1). CD44 is a cell glycoprotein responsible for cell interactions, migration, as well as
adhesion. While this information does not present quantitative information regarding
the amount of CD133 present on the CSCs, it does validate our purchase of CSCs.
However, not all tumor cells express the CD133 cell surface ligand [4]. The amount
of CSCs containing the CD133 marker is also not consistent. One study analyzed
three different primary GBM tumor cell lines and found the following percentages of
CD133+ cells by analysis of flow cytommetry amongst the cultures: 10.2%, 69.7%,
and 27.5% [19]. It is thought that the CD133+ cell population is one of select cell
populations that are responsible for the tumor recurrence based on a study by Singh
et al. who analyzed the ability of CD133+ and CD133- GBM CSCs to form tumors
in mouse in vivo models [4]. As few as 100 CD133+ CSCs were sufficient to form
tumors, yet up to 100,000 CD133- CSCs did not form tumors [4]. Therefore, a tumor
5hierarchy likely exists within a single tumor that may start with the CD133+ cells
for certain tumor types.
1.2 Glioblastoma standard of care
Treatment of GBM initially begins with surgical resection [12]. Complete resection
is rarely attained because the highly infiltrative margins of the tumor are not visible
on conventional MR imaging [3]. The decision of how much to resect is based on
assessment of morbidity verses mortality when operating near eloquent areas. After
surgery, radiation combined with chemotherapy are then initiated as soon as possible,
but begins anywhere from one to four weeks later [3]. All patients are administered the
chemotherapy drug temozolomide (TMZ) sold as Temodar with the chemical name 3-
methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide] [20]. TMZ is given orally
according to the Stupp regimen at a dose of 75 mg/m2 daily for six weeks concurrently
with radiation [21]. The focal radiation is given in fractions of 2 Gy for five days a
week to total 60 Gy. After a one month rest, the patient is then started on six cycles
of adjunvant TMZ at a dose of 150 to 200 mg/m2 for five days every twenty-eight
days [21]. TMZ was initially approved by the US Food and Drug Administration
(FDA) for its treatment of adult GBM patients in 2005 and remains the first-line
chemotherapy drug [20].
During or following therapy, the tumor initially responds, but often recurs. The
standard of care is well-defined after the initial diagnosis, but after recurrence the
standards are much less defined [22]. Serial MRI is conducted for continuous moni-
toring of the treatment course. Figure 1.2 represents a typical progression through
treatment and diagnosis for a GBM patient [3]. MRI is the standard of care imaging
modality; however, it is important to note that there are limitations because it can be
difficult to differentiate between a rapidly progressing tumor and radiation-induced
necrosis for many patients [23]. Differentiating tumor progression from treatment
related change would benefit greatly from ongoing treatment decisions. Tumor re-
6currence, from the subset population of CSCs, are difficult to differentiate from the
abnormal inflammation induced by radiation damage [24].
Fig. 1.2 Treatment tumor timeline. The above figure demonstrates a rep-
resentative timeline of events a patient diagnosed with GBM would un-
dergo during their course of treatment.
1.3 Temozolomide
TMZ is a deoxyribonucleic acid (DNA) alkylator, which nonspecifically methy-
lates DNA [20]. There are two types of DNA alkylation. The first is monofunctional,
which forms an adduct with DNA as it binds. The second is a biphasic process re-
sulting in cross-linking of DNA [25]. TMZ is monofunctional and is rapidly converted
into its active metabolite 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC)
at physiological pH. MTIC is unstable at both low and high pH and rapidly converts
to 5-amino-imidazole-4-carboxamide (AIC) and methyldiazonium ions [25].
Methyldiazonium ions work as electrophiles to alkylate the DNA in a monofunc-
tional manner. TMZ methylates at N3-adenine, N7-guanine, and O6-guanine sites,
arresting the cell at the G2/M phase [20]. As a DNA alkylator, TMZ not only arrests
the cell cycle of tumor cells, but also non-specifically alkylates normal hematopoietic
stem cells causing an unwanted side effect [5]. TMZ has poor serum stability with a
short half-life of 1.8 hours, necessitating multiple doses [26]. Tighter control of the
treatment regimen is required to prevent systemic side effects since TMZ is known to
7cause lymphopenia, thrombocytopenia, and myelodysplasia [27]. Even though TMZ
is used as the standard of care therapy, there are a variety of reasons why GBM
becomes resistant to TMZ over time. First, GBM tumors have infiltrative properties
which allow the tumor cells to extend deep into brain tissue often in a manner beyond
that which can be seen with contrast enhanced imaging making complete surgical re-
section difficult [12]. Another challenge is the presence of the blood brain barrier
(BBB) which is a highly restrictive barrier to protect the brain from the outside en-
vironment. The BBB comprise endothelial cells that form tight junctions to separate
the brain from the circulatory system [17] [28]. The BBB likely restricts passage of
100% of large molecules and 98% of small molecules [17]. For TMZ delivery, 100%
of the drug is absorbed with oral delivery, but only 17% of the administered drug
makes it to the target location into the brain interstitium [29]. The BBB contains
many p-glycoprotein pumps that act as gatekeepers to prevent entry of chemotherapy
drugs by pumping TMZ back out of the brain [30]. Once TMZ converts to MTIC,
the compound is rapidly degraded into its byproduts that facilitate DNA alkylation;
therefore, the implementation of a delivery vehicle could potentially prolong the cir-
culation time of TMZ to prevent alkylation prior to its delivery to the GBM tumor
site.
Temozolomide resistance
TMZ in conjunction with radiation is usually successful initially, but the majority
of GBM recurs in the first year [3] [17]. Within the genome of a GBM cell, the IDH
gene leads to treatment resistance and the presence of wild-type IDH is a predictor
of a poor response to a high dose of TMZ [31]. IDH is involved in many cellular
processes including the citric acid cycle [32]. Patients with normal or wild-type IDH-1
correlate to a shorter survival, compared to those with IDH-1 mutations [15]. IDH-1
and IDH-2 both work to block stem cell differentiation and increase both vascular
endothelial growth factor (VEGF) and hypoxia within the tumor environment [32].
8All are contributing factors to TMZ resistance. In addition, IDH mutations are not
present in the majority of GBM tumors and occur more commonly in grade II or III
gliomas [33].
The high rate of GBM recurrence is in part due to the presence of a highly re-
sistance population of GBM CSCs that lie within the tumor [34]. CSCs can readily
generate both proliferating progenitor-like and differentiated tumor cells amid mi-
croenvironment cues; therefore, a small population of CSCs can potentially lead to
complete regrowth of the tumor which adds to the high probability of recurrence and
poor prognosis [35]. CSCs have a highly developed DNA damage response (DDR)
system which can repair DNA damage caused by TMZ and other chemotherapeutic
drugs and avoid apoptosis. From CSCs, resistance is thought to be due to either
increased expression of MGMT, which can reverse the TMZ-induced methylation, or
from reduced expression of tumor suppressor p53 as a result of high inhibition [20].
The MGMT gene encodes a DNA-repair protein to fix any DNA alkylation from
TMZ [36]. When the promoter for this gene is methylated, it leads to a more positive
prognosis because MGMT is unable to be over-produced [14]. CSCs typically have
an over-expression of MGMT leading to rapid DNA repair after TMZ alkylation.
In addition, the tumor suppressor p53 is negatively regulated by mouse double
minute 2 (MDM2). Over-expression of MDM2 inhibits p53’s ability to reduce the
tumor’s oncogenic effects and send the cell down the apoptotic pathway [37].
1.3.1 Combination therapy
Because of high TMZ resistance as a result of the upregulated DDR system, TMZ
itself is not a viable long term treatment option for GBM. Therefore, development
of combination therapies are critical to treatment of GBM. For instance, an MDM2
inhibitor could provide the additional treatment to overcome TMZ resistance and
eliminate residual CSCs. As discussed previously, MDM2 inhibits p53. Figure 1.3
9represents a schematic showing that if MDM2 were inhibited by an antagonist, p53
would have the opportunity to accumulate and begin tumor suppression [38].
Fig. 1.3 Small-molecule inhibition of MDM2. An MDM2 antagonist can
bind to MDM2 which will prevent the inhibition of p53. This would serve
as an attempt to stabilize the p53 tumor suppression pathway.
Idasanutlin (RG7388, R05503781) is of the nutlin class of MDM2 inhibitors and
possesses enhanced binding specificity, as well as more than 100-fold selectivity com-
pared to its predecessor, RG7122 [39]. RG7388 has good systemic exposure, is
metabolically stable in vivo, BBB permeable, and non-genotoxic [39] [40]. Prelimi-
nary data from Wang et al. has shown that both TMZ and RG7388 in combination
produce a greater than expected, or a synergistic effect, in a primary GBM10 cell
line and RG7388 is a viable treatment option in wild-type p53 GBM cell lines [37].
Therefore, TMZ and RG7388 provide a promising option for a combination therapy.
Both of their mechanisms are outlined in Figure 1.4. As shown in Figure 1.4.A, TMZ
enters the cell and converts to MTIC. The resulting methyldiazonium ions alkylate
the DNA in the nucleus to send the cell towards apoptosis. Because of the increased
DDR in the tumor, the cells become TMZ resistant. RG7388, as shown in Figure
1.4.B, also enters the cell and inhibits MDM2 in the nucleus. This results in the
10
accumulation of p53. P53 is involved in many cellular processes. Loss of p53 allows
expansion of the cells and in normal cells its presence will halt the cell cycle to allow
time for repair [41] [42]. An outline of the total result of these drugs in combination
is seen in Figure 1.4.C.
Fig. 1.4 TMZ/RG7388 combination therapy mechanism. (A) represents
the mechanism that TMZ undergoes to send the cell towards apoptosis.
(B) represents the mechanism RG7388 undergoes to kick start the p53
tumor suppression pathway. (C) represents the overall result of the two
drugs in combination.
Paclitaxel (PTX) is another promising chemotherapeutic agent with many impor-
tant characteristics to provide a powerful combination therapy with TMZ. PTX is
an anti-microtubule agent, which binds to the β-tubulin subunit and stabilizes mi-
crotubules, resulting in disruption of microtubule dynamics and mitotic apparatus
during cell division [43] [44] [45]. A recent study also found that PTX can stimulate
autophagy and induce apoptosis [46]. However, PTX is a strong p-glycoprotein sub-
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strate, and thus has limited distribution across the BBB [47]. Since TMZ and PTX
inhibit the proliferation of tumor cells through different mechanisms, cross-resistance
can be minimized. TMZ and PTX are chosen as a second option for combination
therapy. Their mechanisms are outlined in Figure 1.5. In Figure 1.5.A, the same
mechanism of TMZ occurs as was described previously. PTX works as a second hit
to the tumor cells, potentially removing those that are TMZ resistant. In Figure
1.5.B, PTX enters the cell and binds to the β-tubulin. This suppresses microtubule
detachement from centrosomes during mitosis and leads to a failure in cell division
and ultimately further expansion of the tumor.
Fig. 1.5 TMZ/PTX combination therapy mechanism. (A) represents the
mechanism TMZ undergoes to induce apoptosis in tumor cells. (B) shows
the mechanism PTX uses during a tumor cell’s mitosis that induces apop-
tosis.
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1.4 Nanosystems
To date, single drug therapies have largely failed against GBM. Delivery systems
at the nanometer level that allow therapeutic multi-drug combinations would poten-
tially overcome this limitation. NPs have unique characteristics that can be developed
toward this aim to increase concentration levels at the tumor site. If a potentially
highly therapeutic drug cannot cross the BBB, the drug often must be abandoned
in favor of drugs that can cross, even if less potent. Therefore, any nanosystem de-
veloped to treat GBM will need to facilitate passage through or around the BBB.
While many small molecules are unable to cross the BBB, nanosystems may over-
come challenges by eliminating potential interactions along the drug delivery route
or containing molecules that provide a stealth component to decrease recognition
by macrophages. Nanosystems can be further enhanced with disease-specific ligands
that target biomarkers of interest to improve the biodistribution profile. Nanosystems
encompass a variety of specific types including nanogels, nanosuspensions, nanoemul-
sions, and NPs [48]. Micelles, polymeric NPs and hybrid polymer-micellar NPs will
be further discussed.
NPs are compact particles with diameters ranging from 1 to 1,000 nm and are
actively being developed for both therapy and diagnostics [49]. NPs less than 100
nm have many advantages including enhanced solubility, increased bioavailability, in-
creased surface area, and a potential decrease in dose required [50]. NPs may be
composed of biodegradable and non-biodegradable constituents and are further cate-
gorized as polymeric, polymeric micelles, and inorganic, among others [51]. NPs are
composed of three different layers: the outer layer for surface functionalization, the
middle shell containing the NP materials, and the inner core important for encap-
sulating drugs [52]. NP size and surface characteristics can be easily manipulated
for passive or active drug targeting [49]. Other advantages include the ability for
site-specific targeting, ability to utilize various delivery routes, and ability for a more
controlled and longer sustained release of drugs at the target site [49]. There are a
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few disadvantages, however, such that small size and large surface area can lead to
particle-particle degradation and drug loading may be limited with a burst release [49].
To construct a NP, the appropriate method must be chosen based on the materials
and drugs used. Important considerations include the degree of biodegradability of
the NP, desired size, surface characteristics, and drug solubility and stability [50].
While there are many methods of NP fabrication, including solvent evaporation,
ionic gelation, or nanoprecipitation, solvent evaporation will be discussed in detail as
it is most frequently used [53] [54]. Solvent evaporation can be split into single and
double emulsions as shown in Figure 1.6. A single emulsion is chosen typically for
encapsulation of hydrophobic drugs. This type would be characterized by an oil in
water (o/w) emulsion and involves dissolving both drug and polymers into an organic
solvent and emulsifying them, using ultrasonication, in an aqueous medium (Figure
1.6.A) [50]. A double emulsion can be used to encapsulate hydrophilic drugs or both
hydrophilic and hydrophobic drugs. Traditionally, a hydrophilic drug is dissolved
in an aqueous medium that is then emulsified into an oil solution containing the
hydrophobic drug and polymers. The resulting solution is then emulsified into an
aqueous medium, characterized by a water in oil in water (w/o/w) emulsion (Figure
1.6.B). With each emulsion it is required that each solution is completely immiscible
with each other to allow the solvents to disperse evenly into a continuous phase and
form the NP layers [55].
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Fig. 1.6 Single and double emulsion scheme. The above scheme represents
the steps taken during the solvent evaporation method for both a single
(A) and double (B) emulsion.
A surfactant can be used to improve stability of the NPs, increase circulation blood
in vivo, and prevent the NPs from combining together and forming larger particles [49]
[56]. Selection of surfactant concentration is important because a low concentration
of surfactant leads to an increased polydispersity and particle aggregation, while a
high concentration can decrease drug loading [57].
1.4.1 Polymeric nanoparticles
Polymeric NPs are made of organic materials that can become multifunctional
because of further conjugation after NP formation [52]. Polymeric NPs are also the
simplest type often using single-chain polymers [48]. Many polymer chains contain
groups such as carboxylic acids or amino groups that allow molecules to be conjugated
to them for various applications. In addition, polymers can be chosen depending on
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the time needed to release a drug from the system. Polymers with more organic
material, such as methyl groups, will slowly hydrolyze in the body, hence slowing the
release. Some polymer examples used include polylactic acid (PLA), polyethylene
glycol (PEG), polycaprolactone (PCL) and chitosan. Poly(lactic-co-glycolic) acid
(PLGA) is a common polymer used in the fabrication of polymeric NPs and combines
both PLA and PGA. It is advantageous because it is biodegradable by hydrolysis and
is also biocompatible. Varying the ratio of PLA to PGA allows for fine tuning of
drug release, compared to each polymer alone, because as the ratio of PLA:PGA
increases, the rate of hydrolysis decreases, slowing the release of drug. PLGA is also
amphiphilic and spontaneously creates NPs for drug delivery. Chu et al. utilized
PLGA NPs for the delivery of a TMZ-ester for increased drug delivery for GBM [2].
The PLGA NPs were constructed using an emulsion-solvent evaporation technique.
PLGA and the TMZ-ester were dissolved in acetone and dicholormethane (DCM)
and then added to a 1% polyvinyl alcohol (PVA) for sonication. These NPs were
then conjugated to an anti-human ephrin type-A receptor 3 tyrosine kinase antibody
to target GBM intranasally. This antibody was used to target the ephrin type-A
recpetor 3 membrane-associated receptor over-expressed in the vasculature in GBM
tumors. The conjugated NPs were approximately 146 nm and targeted the brain more
effectively than unlabelled NPs as measured by fluorescence imaging in the in vivo
rat models. Traditionally PLGA NPs are used because they are generally regarded as
safe [58]. While Chu et al. was able to deliver the PLGA NPs intranasally, it has been
shown that polymer NP size can be reduced through combination with micelles [58].
Although there is no known ideal size for brain delivery, it is generally thought that
smaller is better.
1.4.2 Micellar nanoparticles
Micelles are amphiphilic surfactant molecules that spontaneously aggregate into
spherical NPs [59]. In an aqueous environment, the hydrophobic head group of mi-
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celles collects towards the center of the spherical particle and the hydrophilic tail
group of the micelles collects towards the outer edges of the particle. Compared
to liposomes, micelles are formed in a similar manner by self-assembly through the
hydrophobic and hydrophilic groups. However, liposomes form a bilayer, similar
to a cell membrane, and have the capability to contain both hydrophilic and hy-
drophobic drugs [59]. Also, liposomes tend to encapsulate smaller micelles on the
inside to create the liposomal structure. One example of liposomes for the treatment
of GBM comes from the fabrication of polyethyleneglycol-carbamyl distearoylphos-
phatidylethanolamine (DSPE-PEG(2000)-NHS) loaded with chemotherapeutic drugs
doxorubicin and erlotinib, then further conjugated with transferrin for mediated tran-
scytosis and and penetratin for enhanced cell penetration [60]. These NPs were fab-
ricated using a thin film hydration, but compared to micelle formation with solvent
evaporation, this method was more laborious. For instance, they used three different
phospholipids with DSPE-PEG(2000)-penetratin, a pH gradient to encapsulate dox-
orubicin and a G100 sephadex column [60]. This fabrication resulted in a particle
size greater than 150 nm and a polydispersity index (PDI) of 0.193. While this con-
struct was effective at decreasing tumor volume over time in mouse in vivo models,
the synthesis of such a construct can take time and be quite costly with the materials
needed. In addition, this construct lacked a targeting moiety to effectively target the
GBM tumor directly. This resulted in offsite binding in other organs such as the
spleen and heart [60].
Micelles are chosen for our NP construct because of their small size. They also can
be integrated into polymers and provide a simpler assembly as opposed to liposomes.
Micelles rely on the principle of self-assembly. One method of inducing self-assembly
involves dissolving block copolymer micelles into water-immiscible solvents. This so-
lution is then dispersed amongst a continuous aqueous environment [55]. As the
water-immiscible content exits the micelle, the self-assembly occurs to increase the
surface area of the particle [55]. Micelles are beneficial because of their advantages
in delivering hydrophobic drugs as well as their small size. Some examples of poly-
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mers that have been incorporated into micelles include poly(ethylene oxide) (PEO),
poly(propylene oxide) (PPO), polystyrene (PS), and PCL [59] [55]. One example of
micelles utilized for the treatment of GBM inlcudes the use of PCL and methoxy-PEG
copolymer [61]. Methoxy-PEG-PCL encapsulated both doxorubicin and honokiol for
co-delivery. PCL formed the hydrophobic core while PEG was effective at stabilizing
the shell of the NP in an aqueous environment. The NP size was 34 nm and showed
strong anti-cancer effects such as tumor cell apoptosis, decreasing cell proliferation
and tumor angiogenesis compared to single drug micelles [61]. While these NPs were
effective at treating the tumor, they lacked functional groups to provide a theranos-
tic approach. Micelles are effective delivery vehicles. However, their small size may
lead to rapid clearance and may suffer from low drug-loading capacity [49] [58]. In
addition, compared to polymer NPs, micelles lack strong intermolecular interactions
with the encapsulated drug causing premature leakage [58].
1.4.3 Polymer-micellar nanoparticles
Polymer-micellar NPs have the opportunity to combine many of the advantages
of polymer NPs and micelles while potentially avoiding some of their respective dis-
advantages. For instance, the polymer component provides structural stability while
the micelle component allows decreased size [59] [58]. In addition, compared with
traditional micelles, the combination of both components escapes rapid excretion,
seen with micelles, as polymeric NPs have the ability to sustain drug relesase over
time. Micelles are known to clear because they have hydrodynamic diameters similar
to globular proteins and it has been shown that globular proteins of approximately
5-6 nm are associated with the ability to clear via renal filtration or urinary excre-
tion [62]. The larger size of polymer-micelles prevents the rapid clearance. Nabar et
al. produced polymer-micellar NPs containing both PLGA and poly(styrene-block -
ethylene oxide) (PS-b-PEO) [58]. PLGA/PS-b-PEO particles with a polymer:micelle
ratio equal to five achieved a particle size of about 50 nm. These particles achieved
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a sustainable drug release characteristic across 25 days. However, the NPs lacked
functional characteristics such as the ability to target a specific tissue or disease or
to track via imaging. Based on many proposed advantages of polymer-micellar NPs,
we chose this nanosystem for combination therapy.
1.4.4 Targeting cancer stem cells with nanoparticles
While CSCs appear to be a driver of GBM tumor recurrence and drug resistance,
they may also hold the key to improved therapy, if not a cure, if they can be selectively
targeted. Along with CD133, glioma CSCs also express other biomarkers including
CD44, CD95, Nestin, and GFAP, which provides additional potential options for
glioma CSC targeting [63]. Recent studies have shown the AC133 epitope on CD133
is a more specific marker for CSCs [4]. During CSC differentiation, the AC133 epitope
becomes sequestered, which is therefore only present during its undifferentiated state.
This provides an important opportunity for targeting the undifferentiated CSCs in
a selective manner. Given the difficulties associated with developing antibodies to
the AC133 epitope, aptamers are instead being developed because of their ability to
conform to any three-dimensional shape to reproduce the active binding site of the
target ligand. Additional advantages of aptamers include reduced immunogenicity
which prevents premature clearance, high reproducibility, stable conformation, and
much smaller size compared to antibodies, which may increase the likelihood of cross-
ing cellular barriers. Figure 1.7 shows a representation of the potential size increase
when conjugating an antibody to the NPs. Figure 1.7.A shows the 120 kDa antibody
with the aptamer embedded to specifically target the CD133 epitope. Conjugating
the entire antibody may result in an increase in size. Figure 1.7.B shows the fifteen
base pair aptamer specific to the epitope that can be conjugated to the NPs and
potentially maintain similiar size.
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Fig. 1.7 Conjugation of aptamer compared to antibody. (A) represents
the antibody being conjugated to the nanoparticles, potentially increasing
size. (B) represents the aptamer being conjugated to the nanoparticles,
potentially maintaining size.
Aptamers have been previously conjugated and used as a targeting agent in drug
delivery via nanosystems. Gui et al. used an aptamer for CD133 to conjugate lipid-
polymer NPs for drug delivery to osteosarcoma initiating cells [64]. Addition of the
aptamer increased the size of NPs by only 7 nm. In an in vivo model of BALB/c nude
mice bearing an osteosarcoma xenograft of Saos-2 cells, the targeted particles reduced
tumor size more avidly compared to nontargeted NPs [64]. Shigdar et al. identified
and produced a 15 nucleotide RNA aptamer (5’-CCCUCCUACAUAGGG-3’) con-
formation that binds to the CD133 epitope for greater penetration and more stable
uptake into tumorspheres generated by either colorectal cancer cells or embryonic
kidney cells [65]. Therefore, using this aptamer in a drug delivery system can poten-
tially enable a highly efficacious, site-specific therapy, thereby reducing unintended
side effects.
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1.4.5 Modifiying nanoparticles
NPs can be modified to carry a variety of different molecules for both target-
ing and imaging. Targeting agents include proteins, peptides, nucleic acids, and
small molecules [66]. One way to conjugate an aptamer to NPs is through an
N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC) reaction. NPs containing polymers like PLGA contain a carboxylic acid at
its end and EDC is used to activate the carboxylic acid group to facilitate binding
to NHS. This then allows the covalent bonding of primary amines found on aptamers
to the NHS group. EDC reacts with the carboxylic acid and forms an O-acylisourea
intermediate that is displaced by the primary amine. NHS is used to improve the
efficiency of the binding by forming a more stable intermediate (Figure 1.8).
Fig. 1.8 The above figure represents the chemical pathway followed during
an NHS/EDC reaction to form a covalent bond between a carboxylic acid
on NPs and a primary amine on aptamers.
We can use a PLGA that contains an NHS group as opposed to a carboxylic acid.
Because the amine reactive NHS ester is already within the NPs, this eliminates the
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need for the use of EDC which may provide toxicity to in vitro studies if not fully
removed.
The versatility of NPs allows a vast array of options for developing imaging-based
contrast agents. One example is through the use of zirconium-89 (89Zr) for positron
emission tomography (PET) imaging given its high 511 keV gamma emission [51].
89Zr was originally utilized for antibody labelling because its longer half-life of 78
hours corresponds with the three day half-life of circulating therapeutic antibodies.
This allows an optimal amount of time for labeling the NPs and the ability to monitor
the biodistribution of NPs in vivo over time. To effectively chelate the 89Zr to the NPs,
deferoxamine (DFO) is used as a chelating agent. DFO is a hexadentate siderophore
that has the ability to chelate metals through three hydroxamate groups [67]. First,
the DFO is covalently conjugated to an amino group on the NPs through amide
formation. The 89Zr is then contained on the inside of the DFO in a ring-like structure
to allow for imaging of the NPs. The goal is to maintain the 89Zr covalent bond to
the NPs throughout their time travelling to the tumor and this can modelled with
labelling efficiency studies. Using this process, Veronesi et al. was able to achieve a
60% binding efficiency when labelling polymer micellar NPs using DFO [68].
1.4.6 In vitro analysis
The in vitro setting is important for testing the effectiveness of new therapies.
When testing multi-drug delivery vehicles, it is important to understand the cyto-
toxity of the encapsulated drugs alone, in combination and packaged in the vehicle.
To determine the cytotoxic effect of the various treatment groups, the Chou-Talalay
method outlined by Chou et al. and is used to predict drug cytotoxicity and the
effects of combining therapeutic agents during in vitro studies [69]. In combination,
cytotoxic drugs can produce three different effects: an additive effect, a synergistic
effect or an antagonistic effect. An additive effect is the effect that would be pro-
duced if the fractional effect of each drug in combination is equal to one as if the
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two drugs were the same. A synergistic effect is when two drugs produce an effect
greater than an additive effect, while an antagonistic effect is an effect less than an
additive effect [69]. Drugs in combination can be analyzed using a combination index
(CI) rather than assessing for statistical difference in cytotoxicity to depict synergism
(CI<1), additive effect (CI=1), or antagonism (CI>1) [70]. The median effect or
the IC50 value represents the predicted drug concentration where 50% cell killing is
expected, which we can assess with the mathematical software CalcuSyn 2.0. The
Chou-Talalay method is used in the analysis by CalcuSyn 2.0, but some background
information is needed. First, drug potency and the shape of the dose curve (m) is
considered in the mathematical analysis. The fractional product concept is based
on the idea that a drug alone produces a sigmoidal or flat sigmoidal curve of effect.
During a dose curve analysis, the fraction of cells killed is the fraction of cells affected
(Fa). The fraction unaffected (Fu) is determined by the following equation:
Fu = 1− Fa (1.1)
The median-effect equation is used to describe the dose-effect relationship [69]:
Fa
Fu
= (
D
Dm
)m (1.2)
In this equation, D is the dose of drug given to produce a specific Fa and Dm is the
median-effect dose or the IC50. The sigmoidal curve can be linearized by rewriting
Equation 1.2 in the following form [69]:
log(
Fa
Fu
) = mlog(D)−mlog(Dm) (1.3)
When plotting dose-effect curves in such a manner, the conformity of the plot can
be manipulated by adjusting the value of the linear correlation coefficient (r). For this
study, a correlation coefficient ≥ 0.95 is generated. By this method, every treatment
dose may not be included for the analysis as they may not fit in the empirical curve;
however, the empirical curve that will provide the best analysis for the IC50. To
determine the CI values, Calcusyn 2.0 uses the following equations from the analysis
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of two drugs alone to determine if they are additive, synergistic, or antagonistic at
each effect [69]:
CI =
(D)1
(Dx)1
+
(D)2
(Dx)2
(1.4)
In this equation, (D)1 and (D)2 refer to the dose of drug 1 and 2 alone that inhibit the
cell system at x% and (Dx)1 and (Dx)2 refer to the dose of drug 1 and 2 in combination
that inhibit the cell system at the same x%. This analysis is important to consider
when encapsulating drugs as a preliminary step because single drugs may produce a
certain potent cytotoxicity, but may be inhibitory when administered in combination.
1.4.7 In vivo imaging
PET is a highly quantitative and sensitive tool that has the ability to depict the
distribution of positron (β+ particle)-emitting radionuclides such as 89Zr [51]. As the
positrons are emitted, they collide with free electons in the body emitting kinetic
energy in the form of two 511 keV gamma photons and this pair is detected by a
PET scanner [51].
While PET is extremely useful in quantitatively and specifically analyzing dis-
tribution of radionuclides, it lacks anatomical features. By coupling images from
MRI with images from PET, we have the ability to determine the biodistribution of
radionuclides bound to NPs in an animal model. To image the biodistribution or
treatment progression of the NPs, combining both MRI and PET can be used. MRI
is a non-ionizing imaging technology that uses a magnet to produce three-dimensional
images [51]. MRI can be used to determine an anatomical layout and can also be
used for determining presence of tumor in the brain.
1.4.8 Intranasal delivery
In addition to potentially improving GBM therapy through combination treatment
and through the use of polymer-micellar NPs, an alternative route may also improve
treatment distribution to the brain. As discussed, the BBB has a barrier composed of
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tight endothelial cells that prevent the passing of most small molecules. Circumvent-
ing the BBB through an alternative route of intranasal drug delivery (INDD) may
at the very least be equivalent to intravenous administration, if not better. When
drugs travel intranasally, they avoid the BBB and rather cross into the brain along
a perineuronal/perivascular route to the brain including across the cribriform plate
(Figure 1.9) [51]. The topic of nose-to-brain delivery and imaging techniques to mon-
itor therapy is extensively being developed, which we have reviewed and published
recently (Appendix 1) [51]. Overall, designing a drug delivery system that has the po-
tential to be distributed both intravenously and intranasally would increase delivery
route options when conducting in vivo studies.
Fig. 1.9 Rat nose-to-brain anatomy. The nose-to-brain anatomy of the rat
highlights the potential routes NPs would take in order to cross into the
brain [51].
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2. OBJECTIVES
1. Produce a polymer-micellar nanoparticles less than 100 nm in size (Figure 2.1.1)
2. Encapsulate both TMZ and RG7388 into the nanoparticles (Figure 2.1.2)
3. Conjugate an aptamer to the nanoparticles to target the CD133 epitope of the
CSC population (Figure 2.1.3)
4. Label a PET radiotracer, 89Zr, to the nanoparticle for future in vivo studies (Figure
2.1.4)
5. Perform in vitro analysis on the nanoparticles in the CSC population and compare
to free drugs (Figure 2.1.5)
Fig. 2.1 List of nanoparticle objectives.
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3. MATERIALS AND METHODS
3.1 Materials
3.1.1 Nanoparticle fabrication
Carboxyl-terminated PS-b-PEO (molecular weight 5,000-b-2,200, Cat No P4090-
SEOCOOH) and carboxyl-terminated PS-b-PEO (molecular weight 9,500-b-18000
Da, Cat No P18154-SEOCOOH) were purchased from Polymer Source Inc. (Mon-
treal, QC, Canada). PLGA (molecular wieght 73,000 Da, Cat No APO60), PLGA-
NH2 (diamine) (PLGA-NH2) (molecular weight 30,000-40,000 Da, Cat No AI062) and
PLGA-N-hydroxysuccinimide (PLGA-NHS) (molecular weight 50,000-80,000 Da, Cat
No AI116) were purchased from PolySciTech (West Lafayette, IN). Poly(vinyl alco-
hol) (PVA) (molecular weight 13,000-23,000 Da, Cat No 348406) and PVA (molecular
weight 31000-50000, Cat No 363138) were purchased from Sigma Aldrich (St. Louis,
MO). Pluoronic F-68 Prill 188 (Material 30085243) was purchased from BASF (Mount
Olive, NJ). Temozolomide (TMZ) (Cat No T2577) was purchased from Sigma Aldrich
(St. Louis, MO). RG7388 (Cat NO HY-15676/Cs-1473) was purchased from Med-
Chem Express (Monmouth Junction, NJ). Paclitaxel (PTX) (Cat No A10689) was
purchased from AdooQ Bioscience (Irvine, CA). Hydrochloric acid (HCl) (0.1N, Cat
No S25354) was purchased from Fisher Scientific (Waltham, MA). Dichloromethane
(DCM) (Cat No AC406920010) was purchased from Fisher Scientific (Waltham, MA).
Formic acid (≤95%, Cat No F0507-500mL) was purchased from Sigma Aldrich (St.
Louis, MO). Acetonitrile (ACN) (Cat No A996-4) was purchaseed form Fisher Scien-
tific (Waltham, MA). Ethyl acetate (Cat No 035909) was purchased from Oakwood
Chemical (Estill, SC).
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3.1.2 Nanoparticle conjugation
Non-fluorescent CD133 aptamer (5’(C6-NH2) CCC UCC UAC AUA GGG 3’ PO
RNA) (Cat No O-5100) was purchased from TriLink Biotechnologies (San Diego, CA).
Fluorescein amidite (FAM)-azide labelled CD133 aptamer (5’ C6-NH2) CCC UCC
UAC AUA GGG (FAM-Azide) 3’) was purchased from Integrated DNA Technologies,
INC. Water (for RNA work) (Cat No BP561-1) was purchased from Fisher Scientific
(Waltham, MA). Tris-Acetate-EDTA (TAE) (10X solution, Cat No BP1335-1) was
purchased from Fisher Scientific (Waltham, MA). 89Zr(HPO4)2 solution was from
Washington University (St. Louis, MO). Deferoxamine mesylate salt, the mesylate
salt of DFO, (DFOM) (≤92.5% (TLC) Cat No D9533) was purchased from Sigma
Aldrich (St. Louis, MO).
3.1.3 Cell studies
Human GBM43 cells were kindly donated from the Simon Cancer Center at
Indiana University. Culture media was Gibco Dulbecco’s Modified Eagle Medium
(DMEM) with 4.5 g/L D-Glucose, L-Glutamine and was purchased from Life-Technologies
(Grand Island, NY) with 10% Fetal bovine serum (FBS) (Cat No 35-016-CV) from
Corning Inc. (Corning, NY) and 1% HEPES buffer (1M pH 7.3, Cat No 118-089-721)
was purchased from Quality Biological (Gaithersburg, MD). Methylene blue (1% in
ethanol, Cat No LC169201) was purchased from LabChem (Zelienople, PA). Human
GBM cancer stem cells (CSCs) (Cat No 36104-41) were purchased from Celprogen
(Torrance, CA). Culture media was Human Glioma Cancer Stem Cells Media with
Serum (Cat No M36104-40S) requested without antibiotics and was purchased from
Celprogen (Torrance, CA). Methylene blue (1% in ethanol, Cat No LC169201) was
purchased from LabChem (Zelienople, PA).
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3.2 Methods
3.2.1 Particle constituent analysis
Determination of 0.5% 13k polyvinyl alcohol viscosity
To determine the viscosity of 0.5% 13k PVA, the Bohlin CVO 100 Rheometer
from Malvern Panalytical (Malvern, UK) was used. The viscosity of the solution was
measured in triplicate and was collected as an average value of the instantaneous
velocity once the instrument levelled off in values.
Analysis of TMZ by UV-Vis spectroscopy
For analysis of NPs encapsulating multiple drugs, methods were developed to
analyze drug content. To analyze TMZ by UV-Vis for the single emulsion NPs,
absorbance was measured at 325 nm, comparable to the literature maximum of 328
nm [5]. A standard curve was made in triplicate.
To improve measurement by UV-Vis spectroscopy, prior to beginning double emul-
sion fabrication of NPs, the maximum wavelength was determined on the UV-Vis
spectrophotometer. A scan from 270 nm to 380 nm was conducted to determine the
maximum TMZ absorption wavelength in dimethyl sulfoxide (DMSO). A standard
curve was generated reading at 332 nm and was prepared in triplicate to measure
drug content.
Analysis of polymers by UV-Vis spectroscopy
To determine if polymers interfere with UV-Vis analysis of TMZ content, ab-
sorbance scans of each polymer dissolved in DMSO was conducted.
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TMZ stability
Because TMZ hydrolyzes at physiologic pH, it was necessary to determine the
stability of TMZ in aqueous solutions at various pH to improve the formulation of
the NPs. TMZ was dissolved in deionized water at pH 3.48 (pH 4), pH 4.87 (pH
5), pH 6.88 (pH 7) and analyzed by UV-Vis spectroscopy scanning from 220 nm to
370 nm to monitor for degradation or the presence of new peaks as an indication of
conversion to MTIC/AIC. Measurements were conducted in triplicate over the course
of two weeks.
Method determination for HPLC drug analysis
High pressure liquid chromatography (HPLC) was used as a quantitative method
for the determination of drug content on an Agilent 1200 Dual-Loop Series Autosam-
pler from Agilent Technologies (Santa Clara, CA). A novel method was developed for
the separation of TMZ and RG7388. TMZ and RG7388 were dissolved in ACN and
were separated using a mobile phase of water and ACN. The samples were injected
through a Zorbax Eclipse C8 4.6 x 150 mm 5 µm column from Agilent Technologies
(Santa Clara, CA). Reference wavelengths for all three methods were set to 332 nm
for TMZ, 273 nm for RG7388, and 227 nm for PTX. Important criteria was that
between each drug component, a flat baseline needed to be established in order to
accurately measure concentration. The first method to separate the two drugs was
using a 50:50 ratio of water and ACN. The injection volume was 3 µL, flow rate was
1 mL/min and the temperature was 40 ◦C. The next method to separate the drugs
used solvent ratios that can be seen in Table 3.2. However, the water was not mixed
with formic acid initially and the flow rate was 1 mL/min with an injection volume
of 3 µL.
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3.3 Nanoparticle fabrication
3.3.1 Single emulsion nanoparticles
A solvent emulsion evaporation system was adapted from previous work of Nabar
et al. to initially fabricate the NPs [58]. To form the oil phase for TMZ-loaded NPs,
200 µL of either 0.1% PS(5.0k)-b-PEO(2.2k) or 0.1% PS(9.5k)-b-PEO(18k) dissolved
in DCM and 20 µL of 5% 50:50 73k PLGA dissolved in DCM were combined with 500
µL of 0.1% TMZ dissolved in 135 µL of DMSO and 2.865 mL of DCM. The organic
phase was vortexed for 30 seconds and added dropwise to 8 mL of 0.5% 13k PVA.
During addition of the organic phase, the solution was sonicated using a Branson 250
probe sonicator from Branson Ultrasonics (Danbury, CT) at constant duty cycle for
five minutes at 20% power over ice. After sonication, the emulsions were stirred at
650 rpm for 2.5 hours to allow the organic solvents to completely evaporate. Figure
1.6.A outlines the process described above for single emulsion fabrication of NPs.
Each sample, unless otherwise noted, was prepared in triplicate. TMZ+RG7388 NPs
were fabricated using the same method, however, the 500 µL of drug added contained
0.1% solution of TMZ and 0.1% RG7388 dissolved in 225 µL of DMSO and 2.775
mL of DCM. Control NPs were fabricated the same way without the drugs added
and consisted of empty PLGA-PS-b-PEO particles, PLGA particles, and PS-b-PEO
particles. PS-b-PEO control micelles were fabricated using 800 µL of 0.1% of PS-b-
PEO to improve polymer concentration.
To purify the NPs, a similar method to Nabar et al. was used [58]. The NPs were
filtered using a 0.45 µm filter to remove any aggregates. NPs were centrifuged at
2,300 rcf for one hour. The supernatant was then removed and replaced with MilliQ
water. This process was then repeated two more times for thirty-minute cycles each.
These low speeds were used for purification in order to prevent aggregation of the
NPs [58].
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3.3.2 Double emulsion nanoparticles
A double emulsification solvent evaporation technique adapted from Xu et al.
was used to prepare the next set of NPs [71]. Prior to choosing a final method for
the double emulsion NPs, many combinations and techniques were tested including
sonication time, molecular weight of PLGA, surfactant type, surfactant molecular
weight, surfactant concentration, technique of transfer and organic to aqueous phase
volume ratios. Table 3.1 outlines the different methods tested during the preliminary
discovery stages. The size of the NPs were the determining factor in selecting the
final method.
The final method for double-emulsion NPs maintained the same PLGA:PS-b-PEO
weight ratio of 1:5 as used in the single-emulsion NPs [58]. To synthesize NPs with
TMZ only, 389 µL of 0.3% PS(9.5k)-b-PEO(18k) was dissolved in DCM for at least 30
minutes and combined with either 324 µL of 1.8% 50:50 73k PLGA or 162 µL of 1.8%
50:50 50k PLGA-NHS and 162 µL of 1.8% 50:50 30k PLGA-NH2 dissolved in DCM
for about 30 minutes. The organic phase was vortexed for 30 seconds. This organic
phase was sonicated over ice using the Branson 250 probe sonicator at constant duty
cycle for 2 minutes at 20% power. Immediately after starting the sonication, 80 µL of
0.4% TMZ in 0.1N HCl, which had been thoroughly dissolved using bath sonication
and applying heat, was added dropwise to form the first emulsion. Once completed,
the first emulsion was added dropwise to 4 mL 0.5% 13k PVA at pH 4 for a second
emulsion at constant duty cycle for 5 minutes at 20% power. An additional 1 mL
of PVA was used to wash the remaining particles from the first emulsion into the
second emulsion. After sonication, the NPs were left to stir for 2.5 hours at 650 rpm
for evaporation of the organic solvents. To fabricate dual-drug NPs, either 43 µL of
0.2% RG7388 dissolved in ethyl acetate or 23 µL of 0.4% PTX dissolved in DCM was
added to the initial organic phase after the 30 second polymer vortex. The entire
organic phase was then vortexed for an additional 30 seconds.
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For this method, the NPs were filtered using the 0.45 µm filter and then were
collected using an Amicon Ultra-15 centrifugal filter from Millipore Sigma (Burling-
ton, MA) with a 100 kDa molecular weight cut off. NPs were added to the filter and
centrifuged at 5,000 rcf for 20 minutes. The NPs were washed with deionized water
pH 4 twice for 15 minutes at 5,000 rcf and for a final wash and centrifugation of 40
minutes at 5,000 rcf. The remaining suspended NPs were then either used imme-
diately or lyophilized in a Labconco freeze dry system, Freezone 4.5 from Labconco
Corporation (Kansas City, MO) until further use.
3.4 Nanoparticle characterization
3.4.1 Size, PDI, and charge by dynamic light scattering
A Malvern Panalytical Zetasizer (Malvern Panalytical, Malvern, UK) was used to
measure the hydrodynamic diameters of the particles through dynamic light scattering
(DLS). Particles were dropped into either water or 0.5% 13k PVA with viscosity values
set to 0.8872 cPs or 2.78 cPs, respectively. The viscosity for 0.5% 13k PVA was used
after the initial discovery stages of double emulsion particle fabrication. The particle
concentration was adjusted in order to maintain a scattered light intensity between
100 and 200 kilocounts per second. Laser illumination was applied at 633 nm and
the detector was set to 90◦. This measurement determined the PDI to serve as a
quantitative analysis of uniformity within the NP sample.
The Malvern Panalytical Zetasizer was also used to measure the zeta-potential or
surface charge of the NPs. Laser illumination was applied at 633 nm and the detector
was set to 90◦. Particle size and zeta-potential were measured prior to collection.
3.4.2 Size and PDI stability of NPs
TMZ-loaded PS-b-PEO+PLGA-NHS/PLGA-NH2 NPs were measured at various
time points in order to assess size and PDI stability when the NPs are stored at 4◦C
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in the 0.5% 13k PVA solution at a pH≤4. Size and PDI were measured with DLS at
time zero, 24 hours, and 8 days.
3.4.3 Transmission electron microscopy
NPs were placed on a formvar/carbon-coated 200 mesh grid from Electron Mi-
croscopy Sciences (Hatfield, PA) and allowed to absorb for three minutes after which
the remaining solution was wicked away. The grid was then placed on a drop of 1%
uranyl acetate in distilled water for three minutes. The grid was allowed to dry on
filter paper. It was then viewed on a ThermoFisher Spirit Transmission Electron Mi-
croscope (Hillsboro, OR), and images were taken with a CCD Camera from Advanced
Microscopy Techniques (Danvers, MA).
3.4.4 Drug encapsulation and drug-loading percentage by UV-Vis spec-
troscopy
The TMZ-loaded NPs were fabricated using the same methods, however, for single
emulsion NPs, five times the initial concentration of TMZ stock was made (0.5%
instead of 0.1%). The evaporated NPs for single and double emulsion were purified
to remove un-encapsulated TMZ using their respective methods. The washed pellets
were dried under vacuum. For measurement of single emulsion NPs, the pellets were
dissolved into a known volume of DMSO and were measured according to a literature
value for the maximum absorbance of TMZ, 325 nm, and were compared to a standard
curve. For measurement of double emulsion NPs, additional steps were taken to
remove absorption interference from PS-b-PEO. The pellets were dissolved in DMSO
to release the encapsulated TMZ into solution. Then, the PS-b-PEO was precipitated
with 0.1N HCl and filterd with 0.22 µm filter. TMZ was then measured by UV-Vis
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spectroscopy at 332 nm and compared to a standard curve. Drug encapsulation
efficiency was determined by the following equation:
EE% =
DrugEncapsulated (mg)
DrugAdded (mg)
x 100 (3.1)
Drug loading percentage was determined by the following equation:
DL% =
DrugEncapsulated (mg)
NanoparticleWeight (mg)
x 100 (3.2)
3.4.5 Drug encapsulation and drug-loading percentage by HPLC
A standard curve of either TMZ or both TMZ and RG7388 dissolved in ACN was
measured with HPLC on the same day as the analysis to avoid any environmental
changes from day to day measurements. The standard curve was made starting with
54 µg/mL of TMZ and 51.6 µg/mL of RG7388 and diluted to make at least five
standards. These were plotted by comparing concentration to area under the curve.
Standards and unknowns were injected at a volume of 100 µL through a Zorbax
Eclipse C8 4.6 x 150 mm 5 µm column. Mobile phase consisted of ACN and water
adjusted to pH 4 using formic acid and the samples were analyzed according to the
following method in Table 3.2.
Table 3.2
Method for HPLC separation of TMZ and RG7388
Time (min) Water (%) ACN (%) Flow (mL/min)
0.0 20.0 80.0 0.8
2.0 20.0 80.0 0.8
7.0 5.0 95.0 0.8
10.0 0.0 100.0 0.8
12.0 0.0 100.0 0.8
13.0 20.0 80.0 0.8
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3.4.6 Conjugation of anti-CD133 aptamer
To conjugate the aptamer to the NPs containing PLGA-NHS, the NHS to amine
reaction was employed following click chemistry. One batch of NPs, containing ap-
proximately 7 mg of NPs were suspended in DNAse and RNAse free PBS at pH 5.
Next, 20 µL of the anti-CD133 aptamer, either fluorescent or non-fluorescent, was
added from a stock solution of 100 µM. The NPs were then protected from light and
stirred at room temperature at 600 rpm for 2 hours. After stirring, the NPs were
collected by ultra-centrifugation using a Centriprep-10 with a molecular weight cut
off of 10 kDa for 20 minutes at 3,000 g. The filtrate contained the free, unbound
aptamer while the substrate contained the NPs bound to the aptamer. The NPs were
then washed using DNAse and RNAse free water and ultra-centrifuged for 15 minutes
at 3,000 g.
To measure the efficiency of the aptamer, the fluorescent anti-CD133 aptamer with
the FAM linker was conjugated. A standard curve consisting of six known standards
was made and measured each time using a Victor 3V 1420 Multilabel Counter from
Perkin Elmer (Waltham, MA). Fluorescence was measured by using an excitation
wavelength of 485 nm and an emission wavelength of 535 nm. The fluorescence of
the aptamer bound to the NPs was then compared to the standard curve. Binding
efficiency was determined by the following equation:
Binding Efficiency =
Bound Aptamer (µmoles)
Initial Aptamer (µmoles)
x 100 (3.3)
3.4.7 Stability of anti-CD133 aptamer
Preliminary studies were conducted to analyze the stability of the aptamer bound
to the NPs. To analyze whether or not the aptamer was stably bound to the NPs,
an electrophoretic mobility shift assay (EMSA) was conducted. NPs were conjugated
to the anti-CD133 aptamer. NPs were ran on a horizontal 1.5% agarose gel for forty
minutes at 150 V in 1X TAE buffer. Lane 1 consisted of 10 µL from a stock solution
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of trypan blue (10 µL), DNAse/RNAse free water (90 µL), and glycerol (2 µL).
Lane 2 contained 10 µL of a stock solution containing free fluorescent aptamer (1
µL), glycerol (20 µL), and DNAse/RNAse free water (179 µL). Lanes 3-5 contained
different batches of conjugated NPs. These lanes were loaded with 10 µL of solution
from a stock that contained 10 µL of aptamer bound NPs and 2 µL of glycerol. The
gel system was placed in ice and protected from light.
To analyze the binding stability over time, the binding efficiency of the aptamer
was measured using the same method as above. The sample was then placed in the
37 ◦C incubator to mimic in vitro conditions. At various time points, the NPs were
centrifuged in a Centriprep-10 centrifugal filter with a molecular weight cut off of 10
kDa for 15 minutes at 3,000 g. The time points were 0 hours, 0.5 hours, 1 hour, 3
hours, and 24 hours. A known volume of NPs with the bound aptamer was collected
and compared against a standard curve by analyzing with the plate reader under the
same conditions previously listed. Due to constraints of time available in the lab, this
experiment was conducted with a sample size of one.
3.4.8 Conjugation of 89Zr
To conjugate 89Zr to the NPs, two different methods were explored for determin-
ing an optimum binding efficiency. First, 1.5 mg of aptamer-conjugated NPs were
dispersed in 2 mL HEPES buffer to neutralize any acidity. The NPs used were washed
with HEPES buffer after conjugation to the aptamer. This was then added to 1 mL of
20 mM deferoxamine mesylate (DFOM) in water, the mesylate salt of DFO. The NPs
were then stirred for one hour at room temperature to conjugate the amine group
and DFOM. Excess DFOM was then removed by ultra-centrifugation for 40 minutes
at 5,000 g using an Amicon Ultra-15 with a molecular weight cut off of 100 kDa. The
NPs were washed with HEPES buffer for an additional spin of 40 minutes at 5,000 g.
89Zr oxalate was neutralized using 60 µL of HEPES buffer and 60 µL of potassium
carbonate (K2CO3). 200 µCi of
89Zr was added to the NPs, mixed and then incubated
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for 1 hour at 37◦C. NPs were then added to HEPES buffer and centrifuged under the
same conditions. This method was conducted in triplicate.
The second method was similar with slight modifications. An entire batch of
aptamer-conjugated NPs containing approximately 7 mg of NPs were washed with
HEPES buffer and suspended in 2 mL of 20 mM DFOM in water. This solution was
stirred overnight at room temperature to conjugate the amine group to the DFOM.
NPs were collected after adding the solution to 10 mL of HEPES buffer with the same
method. NPs were collected from the filter using 7 mL of HEPES buffer and 0.5 mL
of the solution, containing approximately 0.5 mg of NPs, was mixed with 1 mCi of
89Zr and incubated for 2 hours at 37◦C. NPs were then added to HEPES buffer to
neutralize the reaction and were centrifuged under the same conditions. This method
was conducted in triplicate.
3.4.9 Binding efficiency and stability of 89Zr
To determine the binding efficiency of the 89Zr to the NPs, the radioactivity was
measured using a dose calibrator from Biodex Medical Systems (Shirley, NY). The
radioactivity of the NP pellet, the NPs remaining in initial vial, and the supernatant
were all measured to account for all traces of 89Zr. The efficiency was determined by
importing the radioactivity of the following samples:
Binding Efficiency = (
Labelled 89Zr
Labelled 89Zr + Free 89Zr
) x 100 (3.4)
Stability of 89Zr bound to the NPs was only conducted using the first method.
After measuring binding efficiency, the NP pellet was added to HEPES buffer and
allowed to stir in 37 ◦C for 24 hours. The NPs were then collected using the ultra-
centrifugation method previously described and the radioactivity was measured. To
account for radioactive decay, the radioactivity of the entire solution was measured
prior to collection.
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3.5 In vitro analysis
GBM43 cells were cultured with DMEM and supplemented with 10% FBS and
1% HEPES buffer. These cells could be seeded for testing in 96-well plates at approx-
imatley 85% to 90% confluency. GBM CSCs were cultured using the Human Glioma
Cancer Stem Cells Media described above and could be seeded for testing in 96-well
plates at approximately 60% to 80% confluency according to the Celprogen Human
Glioblastoma Cancer Stem Cell seeding protocol. Both cell lines were cultured at
37◦C in a humidified atmosphere containing 5% carbon dioxide (CO2).
3.5.1 Determination of optimal cancer stem cell seeding number
Prior to performing cytotoxicity studies of both free drugs and NPs, a cell seeding
number for the study in 96-well plates was first optimized. To determine the optimal
cell seeding number for CSCs, cells were treated with RG7388. Cells were plated
in triplicate at concentrations of 100 cells/well, 50 cells/well, and 25 cells/well and
left to culture overnight. Cells were then treated with RG7388 at concentrations
of 50 µM, 37.5 µM, 28.13 µM, 21.09 µM, 15.82 µM, 11.87 µM, 8.90 µM, and 6.67
µM. Cytotoxicity was analyzed by the methylene blue assay listed in the following
subsection. The dose curves were then compared to determine the optimal cell seeding
number.
3.5.2 Determination of IC50 Values
To determine the IC50 value for each drug, a methylene blue assay determined
the cytotoxicity at varying doses. GBM CSCs were plated in a 96-well plate at 25
cells/well in a volume of 100 µL and cultured overnight. Media was adjusted to a
series of single drug concentrations as seen in Table 3.3. A vehicle treatment was also
used that obtained the maximum DMSO concentration used. DMSO concentration
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was maintained ≤0.1% of the total media concentration. In addition, studies were
conducted with media controls on each plate.
Table 3.3
Single drug doses
Cell Line Drug Doses
GBM43
TMZ (µM) 3400, 1700, 850, 425, 212.5, 106.3, 56.1, 26.6
PTX (nM) 18.75, 14.06, 7.91, 5.93, 4.45, 3.33, 2.50
CSCs
TMZ (µM) 2000, 1000, 500, 250, 125, 62.5, 31.3, 15.6
RG7388 (µM) 40, 30, 22.5, 16.9, 12.7, 9.5, 7.1, 5.3
PTX (µM) 1600, 800, 400, 200, 100, 50, 25, 12.5
Combination treatments were conducted next. TMZ and RG7388 were combined
for CSC treatment at ratios of 15:1, 50:1 and 500:1 starting with starting TMZ con-
centrations of 600 µM, 500 µM and 500 µM, respectively.
Treatment groups of NPs were empty non-targeted NPs, non-targeted TMZ-
loaded NPs, non-targeted TMZ+RG7388-loaded NPs, and targeted TMZ+RG7388-
loaded NPs in CSCs. The NPs used for in vitro studies were the final formulation of
NPs seen in Table 4.3. The highest treatment for each of the four groups contained
714 µg of NPs and were diluted by half for a total of nine treatments.
Cells were incubated with the treatments for five days. After, the media was
aspirated and the cells were fixed with 100% methanol for 5 to 10 minutes. Methanol
was disposed of and allowed to dry completely. The remaining viable cells were
stained with 70 µL 0.05% methylene blue for 30 to 60 minutes. The plates were then
shaken into the sink, dipped into deionized water to rinse three times, and the water
was flicked out. The remaining water was shaken out onto a paper towel and the
plates were allowed to dry completely. Next, 100 µL 0.5M hydrochloric acid (HCl)
was added using a multi-channel pipette. The plates were mixed by gently tapping
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and read at 600 nm on the plate reader described above. Treatment amounts will be
listed with the results, but goal treatment duration was three trials in three different
cell populations to account for population differences.
To determine the cytotoxicity, Fa and Fu values were determined by Equation 1.1
and the following:
Fa = 1− (AbsSample
AbsMedia
) (3.5)
These values were then plotted and analyzed in CalcuSyn 2.0 to determine an
IC50 value.
3.6 Statistics
Unless otherwise stated, experiments were conducted in at least triplicate and a
standard error of the mean was used. Statistics were conducted with a confidence
value of 95%. A students t-test was used to conduct comparison between groups.
All data was analyzed using a two-tailed, unpaired analysis with the assumption of
unequal variances. The only test that included a paired analysis was that of the size
stability of NPs.
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4. RESULTS
4.1 Particle constituent analysis
4.1.1 Determination of 0.5% 13k polyvinyl alcohol viscosity
Viscosity was measured by averaging the values of the instantaneous viscosity
after the instrument levelled off at a value for viscosity. These levelled values can be
seen in Figure 4.1. An average of the three trials produced a viscosity measurement
of 1.59*10-7 Pa*s or 2.788 ± 2.37*10-5 cPs.
Fig. 4.1 Determination of surfactant viscosity. Above represents the three
trials of the measurement of viscosity for 0.5% 13k PVA with a rheometer.
The data set that is used in viscosity determination is boxed in green.
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4.1.2 Analysis of TMZ by UV-Vis spectroscopy
TMZ in DMSO was analyzed by UV-Vis. For measurement of drug content in
single emulsion NPs, a standard curve was made by measuring the absorbance of
known TMZ concentrations at 325 nm as seen in Figure 4.2.
Fig. 4.2 TMZ standard curve at 325 nm. This standard curve was made
by UV-Vis spectroscopy and was used for analysis of the drug content in
single emulsion NPs.
To determine the maximum wavelength of TMZ in DMSO by UV-Vis, a scan from
270 nm to 380 nm determined that the maximum wavelength of TMZ in DMSO is
332 nm. A standard curve was generated at 332 nm and can be seen in Figure 4.3.
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Fig. 4.3 TMZ standard curve at 332 nm. This standard curve was made
by UV-Vis spectroscopy and was used for analysis of the drug content in
single emulsion NPs.
4.1.3 Analysis of polymers by UV-Vis spectroscopy
To determine if the polymers interfere with analysis by UV-Vis spectroscopy at
332 nm, absorbance scans were measured. It was determined from Figure 4.4 that
PS-b-PEO has absorbance around the region similar to TMZ, while PLGA does not.
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Fig. 4.4 Polymer absorbance scans in DMSO. These polymer scans were
conducted by UV-Vis spectroscopy to determine if either 50:50 73k PLGA
or PS(9.5k)-b-PEO(18k) have absorbance in the same regions as TMZ.
4.1.4 TMZ stability
Scans of TMZ at various pH of aqueous solutions were analyzd by UV-Vis over
time. These scans can be seen in Figure 4.5. The slopes from these curves in order of
increasing pH are -0.0037 nm per day, -0.0057 nm per day and -0.0077 nm per day.
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Fig. 4.5 The above figure represents the stability of TMZ at pH 4 (A), pH
5 (B), pH 7 (C), as well as a linear regression at maximum absorbance of
332 nm (D).
4.1.5 Method determination for HPLC drug analysis
Two different methods were investigated to separate TMZ from RG7388 and TMZ
from PTX. For the first isocratic method, the release times for the TMZ, RG7388
and PTX were approximately 3.00 min, 1.81 min, and 4.10 minutes respectively. The
release times for the three drugs using the second method were approximately 3.09,
6.31 and 3.48 minutes, respectively. The final method used for drug quantification
shortened the release times of TMZ and RG7388 to 1.9 minutes and 3.8 minutes
respectively while a baseline was established between the two drugs. TMZ eluted
with a sharp peak and RG7388 eluted with a much broader peak (Figure 4.6). The
top portion of the figure shows how TMZ releases with a reference wavelength of 332
nm. The bottom half of the figure shows that TMZ can be seen at the same time
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with a reference wavelength of 273 nm, but is at a much lower intensity. RG7388
could only be detected with the reference wavelength of 273 nm.
Fig. 4.6 HPLC of TMZ and RG7388. The above figure represents the
separation of TMZ and RG7388 via HPLC. After TMZ ellutes the baseline
is established and RG7388 ellutes.
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4.2 Single emulsion nanoparticles
4.2.1 Size, charge, and PDI by dynamic light scattering
During the first experiments, TMZ-loaded NPs were made with PS(5k)-b-PEO(2.2k).
Drug-loaded polymer-micellar NPs with this micelle component had approximate vol-
ume distributed hydrodynamic diameters of 152 nm after two trials. After, single
emulsion NPs were made with PS(9.5k)-b-PEO(18k) and led to a significant decrease
in size for TMZ-loaded NPs to 66 nm. Data acquired from DLS measurements for
single emulsion NPs can be seen in Table 4.1. There was a significant increase in size
when comparing empty polymer-micellar particles and empty PLGA particles. There
was also a significant increase in size when TMZ was added into the particles and
again when RG7388 was added into the particles. There was a significant decrease
in PDI when comparing empty micelles to empty polymer-micellar NPs. When com-
paring zeta-potential measurements, there was a significant decrease in charge when
PLGA was included into the particles as zeta-potential decreased from -9.5 mV to
-29.5 mV.
Table 4.1
PDI and Zeta-Potential Values of Single-Emulsion Particles
Particle Description Size (nm) PDI Zeta-Potential (mV)
PS-b-PEO (control) 22±10 0.385 -9.5 ±1.0
PS-b-PEO + PLGA (no drug) 49±1 0.222 -29.5±0.9
PS-b-PEO + PLGA + TMZ 66±2 0.204 -20.4±1.1
PS-b-PEO + PLGA + TMZ + RG7388 259±3 0.188 N/A
PLGA (control) 221±0 0.155 -20.4±1.1
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4.2.2 Transmission electron microscopy
TEM was used to determine the morphology of the NP samples. Figure 4.7
displays images of blank PS-b-PEO micelles (A) and PS-b-PEO + PLGA polymer
micelle NP (B). Next the morphology of the drug-loaded NPs was analyzed and
Fig. 4.7 Representative TEM images of PS-b-PEO micelles (A) and PS-b-
PEO + PLGA polymer micelle NPs (B). Each mag bar correlates to the
above image and is 200 nm.
representative images of TMZ-loaded NPs (A) and TMZ+RG7388-loaded NPs (B)
are shown in Figure 4.8.
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Fig. 4.8 Representative TEM images of TMZ-loaded NPs (A) and
TMZ+RG7388 NPs (B). Each mag bar correlates to the above image
and is 200 nm.
4.2.3 Drug encapsulation and drug-loading percentage by UV-Vis spec-
troscopy
The TMZ-loaded NPs were investigated by UV-Vis spectroscopy to determine
the amount of TMZ in the NPs. First, a standard curve for TMZ at 325 nm was
determined (Figure 4.2). This resulted in a linear equation of y=0.0596x+0.0905.
Three samples of NPs resulted in an average encapsulation efficiency of 0.03% and a
negligible drug-loading percentage.
4.3 Double emulsion nanoparticles
4.3.1 Size, charge, and PDI by dynamic light scattering
Size and PDI were measured by DLS and are reported in Table 3.1. These results
are the sizes and PDI values that are associated with the initial formulation devel-
opment stages for double emulsion NPs. Size was determined by an average volume
distribution. The table labels correlate to the table in the methods where each letter
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description has a particle formulation that is further detailed above. Because the
viscosity value of water was used during measurement of DLS, these results are un-
able to be compared statistically or to the final formulation. However, sizes between
the groups can be compared. It was determined that increasing the concentration of
the PVA surfactant, results in a decrease in hydrodynamic diameter and reduction
of PDI. In addition, swapping PVA for F-68 resulted in an increase in particle size.
An increase in sonication time slightly reduces the size of NPs, but might not have
a great effect. In addition, the use of Tween in the organic layer did not reduce the
size of the particles, but reduced the PDI.
Table 4.2
Size and PDI Values of Initial Formulation Double-Emulsion Particles
Particle Description Size (nm) PDI
A 195±9 0.103
B 380±4 0.111
C 142±7 0.179
D 141±15 0.086
E 263±6 0.128
F 204±6 0.127
G 210±4 0.108
H 225±11 0.152
I 210±11 0.211
J 207±2 0.161
K 169±13 0.185
A final formulation of NPs was selected by choosing the smallest size and a size that
was less than 100 nm set by the initial size objective. These results were conducted
after the initial formulation development in the preceding paragraph and were used
for the rest of the thesis work. Characteristics of these NPs can be seen in Table 4.3
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to accomplish our first objective (Figure 2.1.1). Empty polymer-micellar NPs had a
size of 95 nm and there was a significant decrease in size to 82 nm upon the addition
of TMZ. When both RG7388 and PTX were loaded into the NPs, there was not a
significant change in size. There was a significant decrease in zeta-potential from -7.1
mV to -9.9 mV when RG7388 was added into the TMZ-loaded NPs.
Table 4.3
Characteristics of final double emulsion NP formulation
Particle Description Size (nm) PDI Charge (mV)
PS-b-PEO+PLGA-
NHS/PLGA-NH2
95±3 0.126 -8.0±1.0
PS-b-PEO+PLGA-
NHS/PLGA-NH2+TMZ
82±3 0.175 -7.1 ±0.4
PS-b-PEO+PLGA-
NHS/PLGA-
NH2+TMZ+RG7388
87±2 0.138 -9.9±0.7
PS-b-PEO+PLGA-
NHS/PLGA-
NH2+TMZ+PTX
83±6 0.140 -9.7±1.9
4.3.2 Size and PDI stability of NPs
TMZ-loaded PS-b-PEO+PLGA-NHS/PLGA-NH2 NPs were measured over time
to determine size and PDI stability. Size increased over time, but there was only a
significant increase of size between 0 and 24 hours. PDI did not show a trend and
there was no significant change.
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Fig. 4.9 Size stability of NPs over time. Size of NPs were measured at
each time point. Each bar corresponds with the PDI results seen in Figure
4.10. Significance is represented by an (*).
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Fig. 4.10 PDI stability of NPs over time. PDI of NPs were measured at
each time point. Each bar corresponds with the size results seen in Figure
4.9.
4.3.3 Transmission electron microscopy
TEM was used to determine the morphology of the NP samples. Figure 4.11
displays representative images of the empty and TMZ-loaded double emulsion PS-b-
PEO+PLGA nanoparticles prepared with functional PLGA in the form of PLGA-
NHS and PLGA-NH2. Next the morphology of the dual drug-loaded NPs were ana-
lyzed and representative images of TMZ+RG7388-loaded NPs (A) and TMZ+PTX-
loaded NPs (B) are shown in Figure 4.12.
55
Fig. 4.11 TEM images of control and TMZ-loaded NPs. Above are rep-
resentative TEM images of empty functional NPs (A) and TMZ-loaded
functional NPs fabricated by a double emulsion protocol (B). Each mag
bar correlates to the above image and is 200 nm.
Fig. 4.12 TEM images of TMZ+RG7388 NPs and TMZ+PTX NPs.
Above are representative TEM images of TMZ+RG7388-loaded NPs (A)
and TMZ+PTX-loaded NPs (B). Eahc mag bar correlates to the above
image and is 200 nm.
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4.3.4 Drug encapsulation and drug-loading percentage by UV-Vis spec-
troscopy
Double emulsion NPs containing 50:50 PLGA-NHS/PLGA-NH2 were investigated
initially by UV-Vis to see the potential increase in TMZ encapsulation compared to
the single emulsion method. The NPs had an EE% of 14.20%±3.23% and a DL% of
1.17%±0.46%.
4.3.5 Drug encapsulation and drug-loading percentage by HPLC
Encapsulation efficiency and drug loading percentage were confirmed by HPLC
because of the increased sensitivity over UV-Vis spectroscopy to achieve our second
objective (Figure 2.1.2). A method to separate TMZ and RG7388 was successfully de-
veloped. A representative standard curve for each drug can be seen in Figure 4.13. By
HPLC, the encapsulation efficiency and drug loading percentage of TMZ-loaded NPs
was determined to be 4% ±6.7 and 0.12% ±0.19, respectively. For TMZ+RG7388-
loaded NPs, the encapsulation efficiency was 1.6% for TMZ and 52.8% for RG7388.
The drug loading percentage was 0.07% for TMZ and 0.66% for RG7388.
Fig. 4.13 The above figure contains a representative standard curve for de-
termining the concentration of RG7388 (left) and TMZ (right) by HPLC.
57
4.3.6 Conjugation of CD133 aptamer
The aptamer was bound to the NPs and achieved a conjugation efficiency of 86.3%
± 7.4%. This was conducted to achieve our third objective (Figure 2.1.3) The EMSA
assay was the first method used to determine if the NPs were stably bound to the NPs.
According to Figure 4.14, the free aptamer and aptamer conjugated NPs all shifted ap-
proximately the same distance. Once the aptamer was conjugated to TMZ+RG7388-
loaded NPs, the size of the NPs were 85±3 nm (n=2). In addition, these NPs had
a PDI of 0.113±0.011. These final NPs had a zeta-potential of -25.3±0.3 mV. This
zeta-potential was significantly more negative than the TMZ+RG7388-loaded NPs
without the conjugated aptamer.
Fig. 4.14 EMSA assay for aptamer bound to NPs. The above figure rep-
resents the EMSA assay for NPs bound to aptamers.
The stability of the binding of the aptamer to the NPs was analyzed over a course
of 24 hours. The binding efficiency decreased from 94% to 68% within one hour of
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conjugation. After 3 hours, the binding efficiency was about 50%. From the 3 hour
time point to the end of the 24 hours, the binding efficiency increased to 70%.
Fig. 4.15 Aptamer stability. The above figure represents the stability of
the conjugated aptamer at 37 ◦C over a course of 24 hours.
4.3.7 Conjugation of 89Zr
The first method to conjugate 89Zr to the NPs had a labeling efficiency of 29%
± 2.56% and an average radioactivity of 158.5 µCi. After 24 hours, approximately
46.8% ± 1.6% of the 89Zr released from the NPs. The second method achieved a
significant decrease in binding efficiency to 14% ± 0.9% with an average radioactivity
of 127.7 µCi. This was conducted to achieve our fourth objective (Figure 2.1.4).
4.4 In vitro analysis
4.4.1 Single drug analysis
TMZ and RG7388 single drug analysis was conducted with an n=3 in three dif-
ferent cell populations to achieve one part of our fifth objective (Figure 2.1.5). Dose
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response curves can be seen in Figure 4.16. The Fa and Fu values from these dose
responses can be seen in Table 4.4. These Fa values were plotted using a logarith-
mic analysis to determine the most linear region. These plots can be seen in Figure
4.17. These most linear regions were entered into CalcuSyn 2.0 and produced an IC50
value for TMZ was determined to be 270.02 µM with a lower 95% confidence limit
of 214.64 µM and an upper confidence limit of 339.69 µM. The IC50 for RG7388 was
determined to be 16.14 µM with a lower 95% confidence limit of 14.58 µM and an
upper confidence limit of 17.86 µM.
Fig. 4.16 TMZ and RG7388 alone in CSCs. The above figure represents
the analysis of single drugs in glioma CSCs. The left represents the dose
curve from TMZ alone and the right represents the dose curve of RG7388
alone.
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Table 4.4
Single Drug Dose Responses
TMZ RG7388
Dose Fa Fu Dose Fa Fu
0 0 1 0 0 1
15.63 -0.12 1.12 5.34 -0.10 1.10
31.25 -0.18 1.18 7.12 -0.09 1.09
62.5 0.01 0.99 9.49 0.23 0.77
125 0.19 0.81 12.66 0.30 0.70
250 0.46 0.54 16.88 0.58 0.42
500 0.71 0.29 22.5 0.68 0.32
1000 0.82 0.18 30 0.69 0.31
2000 0.82 0.18 40 0.66 0.34
Fig. 4.17 Linear plots for TMZ and RG7388 dose responses. The left
represents the most linear region from the TMZ dose response curve. The
right represents the most linear region from the RG7388 dose response
curve.
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A PTX dose curve was conducted with an n=3 in one cell population. This dose
curve can be seen in Figure 4.18. An IC50 value was not determined for this drug,
but can be estimated as approximately around 100 nM.
Fig. 4.18 PTX dose curve in CSCs.
A TMZ dose curve was conducted with an n=3 in three cell populations of GBM43
cells. This dose curve can be seen in Figure 4.19. This was unable to be analyzed via
CalcuSyn, but produced an approximate IC50 value of 338 µM. A PTX dose curve was
conducted with an n=3 in four cell populations of GBM43 cells. This dose curve can
be seen in Figure 4.19. This was unable to be analyzed via CalcuSyn, but produced
an approximate IC50 value of 11 nM.
Fig. 4.19 TMZ and PTX single drug dose curve in GBM43 cells.
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4.4.2 Combination drug analysis
TMZ and RG7388 was given in combination to the CSCs. Ratios of RG7388 to
TMZ that were 1:15 and 1:100 were analyzed with an n=3 in three different cell
populations. The ratio of 1:50 was only given to an n=3 in one population.
Table 4.5
Combination Drug Dose Responses
Ratio of 1:15 Ratio of 1:50 Ratio of 1:100
TMZ (µM) Fa TMZ (µM) Fa TMZ (µ) Fa
0 -0.23 0 -0.01 0 0.13
4.69 -0.16 3.91 0.19 3.91 0.19
9.38 0.10 7.81 0.08 7.81 0.15
18.75 0.16 15.63 -0.06 15.63 0.28
37.5 0.11 31.25 0.33 31.25 0.14
75 0.34 62.5 0.42 62.5 0.29
150 0.59 125 0.75 125 0.50
300 0.81 250 0.89 250 0.65
600 0.86 500 0.86 500 0.74
These combinations were analyzed using CalcuSyn 2.0 and 50% effective doses
(ED50) were determined. These doses were the combination of TMZ and RG7388
that produced 50% killing in CSCs. At a ratio of 15, the ED50 is when TMZ is
at a concentration of 122.48 µM. At a ratio of 50, the ED50 is when TMZ is at a
concentration of 82.83 µM. Finally, at a ratio of 100, the ratio is when TMZ is at a
concentration of 153.57 µM. To determine synergy, CalcuSyn 2.0 ran CI simulations
at predicted cell responses. These simulations can be seen in Table 4.6. The IC50
values were plotted and compared to the effect of the drugs alone. This isobologram
in Figure 4.20 shows an additive effect when RG7388 and TMZ are in a molar ratio of
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1:15 and synergistic effects when the two drugs are in molar ratios of 1:50 and 1:100.
This parallels the CI values that were simulated.
Table 4.6
Combination indexes for TMZ and RG7388 in CSCs
Fa CI for Ratio of 1:15 CI for Ratio 1:50 CI for Ratio 1:100
0.02 1.058 0.820 0.245
0.05 0.994 0.677 0.308
0.10 0.961 0.586 0.369
0.15 0.948 0.538 0.414
0.20 0.942 0.505 0.453
0.25 0.940 0.481 0.487
0.30 0.939 0.461 0.520
0.35 0.940 0.444 0.552
0.40 0.942 0.429 0.584
0.45 0.945 0.415 0.617
0.50 0.950 0.403 0.652
0.55 0.955 0.391 0.688
0.60 0.962 0.380 0.728
0.65 0.970 0.369 0.773
0.70 0.980 0.358 0.825
0.75 0.993 0.347 0.886
0.80 1.011 0.335 0.964
0.85 1.035 0.322 1.069
0.90 1.073 0.307 1.232
0.95 1.150 0.289 1.565
0.99 1.393 0.266 2.792
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Fig. 4.20 Isobologram of TMZ and RG7388 in CSCs. GBM CSC growth
was inhibited when exposed to TMZ in combination with RG7388.
RG7388 to TMZ at ratios of 1:50 and 1:100 produced a synergistic ef-
fect. Ratio of 1:15 produced an additive effect.
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4.4.3 Analysis of treatment with NPs
CSCs received treatments of empty polymer-micellar NPs, TMZ-loaded NPs,
TMZ+RG7388-loaded NPs and TMZ+RG7388-loaded NPs conjugated to the anti-
CD133 aptamer as the second part of our fifth objective (Figure 2.1.5). Dose curves
for empty NPs and TMZ-loaded NPs can be seen in Figure 4.21. These two sets of
NPs had minimal cytotoxic effect on the CSCs. Dose curves for dual-drug loaded
NPs and dual-drug loaded NPs can be seen in Figure 4.22. These dose curves were
unable to be analyzed by CalcuSyn 2.0. However, a similar analysis was conducted
to determine an approximate IC50 value. Dual-drug loaded NPs had an IC50 value of
the TMZ concentration of 14.26 µM. The addition of the targeting agent somewhat
lowered the IC50 value to a TMZ concentration of 11.86 µM.
Fig. 4.21 Empty and TMZ-loaded NPs in CSCs. Above represents the
dose curves generated from empty polymer-micellar NPs (left) and TMZ-
loaded NPs (right). The mass of NPs is the same in each dose curve.
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Fig. 4.22 TMZ+RG7388-loaded NPs and targeted TMZ+RG7388-loaded
NPs in CSCs. Above represents the dose curves generated from dual-
drug NPs (left) and dual-drug NPs conjugated to the anti-CD133 aptamer
(right).
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5. DISCUSSION
The quest for a cure for GBM has been disappointing since no new drug has sig-
nificantly impacted patient survival in more than fifteen years [1]. A one disease, one
drug approach is unlikely to be a viable option given the high propensity of GBM for
recurrence, which is at least partially driven by the highly resistant subpopulation
of self-regenerating GBM CSCs [34] [35]. NPs hold great promise for overcoming
the limitations of a single drug approach by permitting multi-drug combinations that
treat GBM synergistically. In addtion, NPs open the door to utilizing the unique ad-
vantages of theranostics since the therapeutic agent can be assessed using an imaging
label [72]. The goal of this thesis was to establish the building blocks of a multi-drug
therapeutic approach that could systematically dismantle GBM by preferentially tar-
geting and overriding the intrinsic TMZ resistance of GBM CSCs. In addition, we
sought to integrate an imaging label that would permit a fully theranostic approach to
GBM. We hypothesized that hybrid functionalized PS-b-PEO and PLGA NPs could
be harnessed to encapsulate two different chemotherapies, TMZ and RG7388, to kill
human derived GBM CSCs in a dose dependent manner in vitro. We also hypothe-
sized that a 15 nucleoside CD133 aptamer could be covalently bound to our dual-drug
loaded PS-b-PEO-PLGA NPs to selectively target the CD133 antigen on the CSC
surface. Third, we hypothesized that chelative binding of the 89Zr radiotracer to the
surface of the NPs would establish a theranostics application for in vivo PET biodis-
tribution studies. Finally, we set a definitive goal to maintain a size of less than 100
nm and acceptable polydispersity to the final dual-drug loaded, functionalized NP.
We made steady progress in addressing our first hypothesis by constructing PS-
b-PEO and PLGA NPs that encapsulated both TMZ and RG7388. Our original goal
had been to maintain a size of 25-50 nm consistently published by our collaborators
from Ohio State (Jessica Winters, Ph.D.) [58].
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We achieved close to 50 nm size, but only during the production of NPs without
drugs and without functional groups. As we added more components to the NPs in a
stepwise fashion, the NPs increased in size above 50 nm, but our final NPs with two
drugs and two functional groups stayed below 100 nm. This accomplished our first
objective (Figure 2.1.1). This is in contrast to dual drug-loaded mPEG-PLA NPs also
encapsulating two drugs (TMZ and PTX), but with a 200 nm size [71]. It is possible
that our hybrid approach using both micelles and polymer improved the size of the
NPs compared with traditional polymer PLGA particles [58] [73]. In the process
of optimizing drug encapsulation, we discovered that a double emulsion technique
modified from Xu et al., permitted dual-encapsulation with both TMZ and RG7388
more efficiently than a single emulsification as reported in the literature [58] [20].
As shown in the results, we reduced the size of dual-drug loaded NPs from 260 nm
down to 85 nm using this technique. Other published studies utilized sizes of NPs
of 275 nm, 300-500 nm, and 206 nm [74] [75] [71]. These results may have been
influenced by use of polymer components consisting of PLGA-PEG-PLGA, PCL,
and PLGA-mPEG [74] [75] [71]. While NPs fabricated by a double emulsification
technique typically result in larger sizes, others have achieved a size as small as 40
nm when co-loading 5-fluorouracil and Chrysin into PLGA-PEG-PLGA NPs [76].
During the production of NPs, we consistently maintained a PDI of 20% or less
which is desirable since lower polydispersity indicates a more uniform size distribution
[77]. As for charge, we also achieved a slightly negative charge for dual drug-loaded
particles, except during addition of the CD133 aptamer, which decreased the zeta-
potential from -8 mV to -25 mV. While the ideal charge is not known, there is a
general consensus that a neutral or slightly negative charge neither repulses the cell
membrane nor binds it too tightly [51]. Finally, dual-drug PS-b-PEO+PLGA NPs
exhibited a consistent spherical morphology when analyzed by TEM and revealed a
low level of clumping even with longer duration in solution. Particles with a more
spherical shape can potentially result in better cell uptake compared to cylindrical
particles as well as increased circulation time [78]. With successful construction of
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TMZ+RG7388 NPs, we sought to assess these NPs compared with blank control NPs
and NPs containing only TMZ. We first demonstrated synergistic killing of CSCs using
combination therapy of TMZ and RG7388, through an analysis of the CI outlined
by the Chou-Talalay method, without using NPs first. Through these results we
determined a reduction in the IC50 value of TMZ from 270 µM when treating CSCs
alone, to 83 µM when in combination with RG7388 at a molar ratio of 50:1. A
prior published study from our collaborator (Dr. Karen Pollok) demonstrated a
synergistic effect between TMZ and RG7388 in the human derived GBM10 cell line,
but to our knowledge, the GBM CSC population has not been treated with this drug
combination [37]. We demonstrated that dual-drug loaded NPs produced a higher
killing effect than empty NPs and TMZ-loaded NPs to acheive our fifth objective
(Figure 2.1.5).
Following our initial cell killing studies with non-targeted NPs, we next sought
to address our second hypothesis to develop the CD133 aptamer binding to the
TMZ+RG7388 NPs. We achieved a high conjugation efficiency of 86% with the
fluorescently-labelled CD133. This accomplished our third objective (Figure 2.1.3).
We attempted to validate these stability results using an EMSA. Although the NPs
are much larger in size compared to the aptamer, charge also influences the degree
to which the compounds will migrate. Both free aptamer and aptamer bound to the
NPs travelled the same distance approximately 60% from the starting point creating
a single well-defined band without a gradient in the EMSA study. Dissociation of
CD133 aptamer from the NPs would produce a non-uniform gradient. A single pre-
liminary study of the stability of CD133 aptamer binding to the NPs revealed 50%
aptamer remained bound to the NPs at 3 hours and 60% still bound at 24 hours.
These results are difficult to interpret since the experiment was performed only once
and needs to be replicated in future trials.
To address the second part of hypothesis two, we sought to demonstrate superior
CSC killing with TMZ+RG7388+CD133 NPs compared with TMZ+RG7388 NPs
without CD133. There was a trend towards a lower IC50 value in CD133 aptamer-
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bound NPs compared to those without the CD133 aptamer. Future in vitro and in
vivo studies need to be conducted to assess the potential advantages of the CD133-
labelled NPs.
Time limited full development of our third hypothesis, but we performed three
trials of labeling the NPs with 89Zr using two different methods. In the first method
we incubated the NPs in a DFOM solution for 40 minutes and labelled with 89Zr
for one hour to achieve 30% labelling. To try to improve labeling, we incubated the
NPs in the DFOM solution overnight and labelled with the 89Zr for two hours. Our
first method achieved a higher amount of 89Zr labelled to the NPs and had a final
radioactivity of 158 µCi on 1.5 mg of NPs. For future in vivo studies, this technique
will need to be optimized to meet the 250 µCi minimum in each dose of NPs for our
current Indiana University IndyPET preclinical system. These initial steps will help
us further acheive our fourth objective (Figure 2.1.4).
One of the main challenges of this work was with the first hypothesis in the
development of dual drug-loaded NPs. Encapsulation efficiency of TMZ in the NPs
was low, but is higher than reported in the literature. One study extensively analyzed
a variety of ways to improve the encapsulation of TMZ and achieved a maximum of 2%
encapsulation [20]. To overcome this challenge, a series of studies were conducted to
understand the stability and optimal environments for using TMZ in the development
of NPs. Even with extensive analysis of TMZ, we were unable to encapsulate TMZ
to a clinically relevant concentration as seen by the negligent killing in TMZ-loaded
NPs. However, even though the encapsulation of TMZ is low in the dual-drug NPs we
are unable to say it does not increase the cytotoxicity in combination with RG7388
until we conduct combination studies at that ratio. Future studies could test delivery
of TMZ orally as part of standard therapy, and then deliver two different drugs more
feasibly encapsulated into the NPs. Such a system would allow a three drug approach
to supplement oral TMZ therapy.
Another barrier to successful TMZ encapsulation was lack of uniformity across
the current published literature with regard to improved formulations of NPs or mea-
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surement techniques. While some publications report encapsulation efficiencies us-
ing a direct measurement of drug content in a pellet of NPs, others use indirect
measurements that may result in an apparently higher, although less accurate en-
capsulation efficiency [71]. To improve data accuracy and minimize unnecessary and
repetitive formulation changes, the nanotechnology community has recently proposed
more standardized protocols for data reporting [79].
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6. CONCLUSION
GBM is a devastating disease with a dismal prognosis and a paucity of effective
chemotherapeutic agents. The increased mutation rate, infiltrative nature and high
propensity for self-renewal of the CSC population are important reasons for failure
of may single drug regimens against GBM. In an attempt to address these, this
thesis outlines a strategy for using multi-functional polymer-micellar NPs to target
the CSC population and deliver a therapy that overcomes GBM resistance to TMZ.
Our polymer-micellar NPs utilized PLGA-NHS and PLGA-NH2 functional groups to
attach a CD133 aptamer and radiotracer while also maintaining a relatively uniform
size of less than 100 nm with a slightly negative charge. Preliminary CD133 labeling
of NPs demonstrated a trend in higher killing of CSCs in vitro compared with CD133
deficient NPs. Addition of PET radiotracer, 89Zr, to our multi-functional CD133
targetable NPs introduced a potential theranostics application to allow real time in
vivo fate mapping.
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7. FUTURE WORK
There were limitations we encountered which would ideally be addressed in future
work. The most important and time consuming limitation evolved around the diffi-
culty we encountered with encapsulating TMZ. Options would be to either replace
TMZ with a suitable anticancer drug or try a different encapsulation approach. For
instance, a w/o/o phase separation in a non-aqueous medium could be studied. In
this method, both hydrophilic and lipophilic drugs can be encapsulated while avoid-
ing the possibility that aqueous solutions wash away hydrophilic drugs [80]. Instead
of emulsifying the components in a larger volume of aqueous solution, the hydrophilic
drug is mixed into an organic solvent in the presence of an organic nonsolvent, such
as silicone oil, that will not dissolve either drug or the polymers [80]. As the organic
solvent evaporates, this forces the polymers to undergo a phase separation and the
polymer will adsorb onto the drug [80]. This method may increase the encapsulation
of TMZ, but result in a size increase of our NPs.
If we were to eliminate TMZ from the particle system and use it as an oral agent
we would develop new dual-drug NPs. Given the much higher potency of RG7388 we
encountered in treating CSCs, TMZ encapsulation may need to increase significantly
for a combination effect to be discerned. While studying drug effects on CSCs in
the absence of NPs, we were able to utilize much higher concentrations of TMZ for
comparison with RG7388. Higher amounts of RG7388 and low TMZ may result
in predominately RG7388-induced toxicity. We could try to encapsulate RG7388
with another potent hydrophobic drug such as PTX that offers better encapsulation
efficiency and greater cell killing. Preliminary data on the effectiveness of PTX in
both CSC and GBM43 cell lines can be seen in the results as it seems to act more
potently against GBM compared to even RG7388.
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Additional studies to show the potential benefit of CD133-targeted NPs need to
be conducted. Our current experiments show a slight increase in cytotoxicity with
the addition of the CD133 aptamer to the NPs. However, because this increase had
not been yet shown to be a significant change, the drugs may be releasing into the
wells regardless of whether or not the NPs were bound to the CSCs. First, we need to
conduct additional cytotoxicity trials. Next, to better assess the targeting ability of
our CD133-labelled NPs we could try two different fluorescent techniques. The first
option would be to assess uptake of CD133 targeted and non-CD133 targeted NPs
into cells using fluorescence correlation spectroscopy (FCS) which assesses whether
particles are taken into cells in vitro by the presence of a diffusion coefficient measured
by the fluorescent marker. We conducted initial studies to determine the diffusion
coefficient of NPs bound to the fluorescent aptamer by suspending them in water.
However, during these studies, we were unable to accurately measure this value as
the NPs seemed to produce a flickering effect, which introduced inconsistencies in the
correlation analysis not to stabilize. Once the diffusion coefficient is determined, we
can treat the aptamer-conjugated NPs in populations of CSCs. These plates would
need to be either 24-well or 6-well plates to increase the amount of CSCs plated.
These CSCs could be treated for perhaps 24 hours with the aptamer-conjugated NPs,
fixed with paraformaldehyde and then analyzed using FCS. If the CSCs take up the
NPs bound to the aptamer, we would see an increase in the diffusion coefficient. To
compare targeted verses non-targeted NPs, we could label either the PLGA or the PS-
b-PEO with a fluorescent dye such as Cy5 dye and analyze whether or not more CSCs
take up the targeted or non-targeted CSCs. Second, fluorescent imaging microscopy
could be performed permitting image acquisition of the Cy5 labelled NPs to assess
cell uptake of targeted verses non-targeted NPs. Images could also be taken analyzing
the uptake ability of CD133+ CSCs and the CD133- CSCs. To do this, we would
need to sort the CSC population using fluorescence-activated cell sorting (FACS) by
immunostaining the CD133+ population prior to sorting. We could also conduct this
study in a co-culture with CD133+ CSCs and differentiated neuronal stem cells that
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are determined to be CD133-. This would account for any non-specific targeting.
Finally, differential killing of CD133 and non-CD133 labeled NPs may ultimately
be further assessed in vivo since drug is released into the medium and subsequently
enters the cells independent of the targeting of the NPs. In vivo may be the best
route to fully demonstrate proof of targeting.
Future improvements of the labelling of 89Zr also need to be made. In vivo studies
can not be performed until we can label more 89Zr to the NPs. One way to improve
the labelling efficiency could be through the use of an alternate chelating agent.
Previous work by Veronesi et al. used a derivative of DFO that was attached to a
benzyl isothiocyanate (DFO-Bz-NCS) [68]. Furthermore, another study showed an
increased in binding and stability using DFO* as part of the above derivative which
adds an additional hydroxamic acid function to the chelate chain compared to DFO
alone [81].
In summary, important progress was made in vitro towards the formation and
initial testing of a multi-functional theranostics nanoparticle that can be used to
target and treat the CSC specific cell population with GBM. This thesis comprised a
significant portion of the in vitro arm of the project. The second arm of the project
will be to test our compound in vivo in a preclinical model of GBM for both therapy
efficacy and fate mapping.
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Abstract: Intranasal (IN) delivery is a rapidly developing area for therapies with great potential for the treatment of 
central nervous system (CNS) diseases. Moreover, in vivo imaging is becoming an important part of therapy assess-
ment, both clinically in humans and translationally in animals. IN drug delivery is an alIn fact, imaging hasternative 
to systemic administration that uses the direct anatomic pathway between the olfactory/trigeminal neuroepithelium 
of the nasal mucosa and the brain. Several drugs have already been approved for IN application, while others are 
undergoing development and testing. To better understand which imaging modalities are being used to assess IN 
delivery of therapeutics, we performed a literature search with the key words “Intranasal delivery” and “Imaging” 
and summarized these findings in the current review. While this review does not attempt to be fully comprehensive, 
we intend for the examples provided to allow a well-rounded picture of the imaging tools available to assess IN 
delivery, with an emphasis on the nose-to-brain delivery route. Examples of in vivo imaging, for both humans and 
animals, include magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission 
computed tomography (SPECT), gamma scintigraphy and computed tomography (CT). Additionally, some in vivo opti-
cal imaging modalities, including bioluminescence and fluorescence, have been used more in experimental testing 
in animals. In this review, we introduce each imaging modality, how it is being utilized and outline its strengths and 
weaknesses, specifically in the context of IN delivery of therapeutics to the brain.
Keywords: Intranasal drug delivery, theranostics, multimodality imaging, blood-brain barrier
Introduction
The blood-brain barrier (BBB) is highly success-
ful at protecting the brain from entry of poten-
tially detrimental substances. Unfortunately, 
greater than 99% of potential therapies are 
also greatly restricted from entering the brain 
[1, 2]. Therefore, there is an urgent need to 
develop alternative delivery strategies for get-
ting therapies around the BBB non-invasively. 
Intranasal (IN) delivery is a promising alterna-
tive to systemic administration that uses the 
direct anatomic pathway between the olfacto-
ry/trigeminal neuroepithelium of the nasal 
mucosa and the brain. Since only small 
amounts of a drug are delivered to the brain 
using this route, the mechanism of delivery 
needs to be better understood and new meth-
ods need to be developed to overcome the 
obstacles facing nose-to-brain delivery of prom-
ising therapeutics. The key to overcoming these 
challenges and furthering the field of IN deliv- 
ery is to develop informative, non-invasive 
methodologies to better understand the nose-
to-brain delivery pathway. One important tool 
at our disposal is through the use of in vivo 
imaging. In fact, imaging has great potential 
to facilitate the translation of promising IN 
therapies from animals to humans and im- 
proved imaging techniques continue to emerge. 
Prior to discussing the imaging aspect, we will 
introduce the concept of IN delivery, explore 
the latest information regarding the most like- 
ly path from nose-to-brain and discuss various 
types of therapies that would benefit from IN 
imaging assessment. In particular, we lay the 
groundwork for the importance of developing 
theranostic agents for both therapy and diagno-
sis in one platform.
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The nasal cavity is well-suited for therapy deliv-
ery since the nasal mucosa has a high relative 
permeability, thin endothelial membrane and 
reasonable surface area for absorption of not 
only small molecules but also macromolecules 
such as proteins and peptides, nucleotides, 
viruses and even stem cells [3-5]. In particular, 
nose-to-brain therapy delivery has garnered 
high interest given the high failure rate of 
drugs that are unable to bypass the BBB [6]. 
Examples of difficult-to-treat central nervous 
system (CNS) diseases include brain malignan-
cies, neurodegenerative diseases, stroke, sei-
zures and psychiatric diseases, among others 
[7]. Understanding the mechanism of delivery 
and fate of drugs that can bypass the BBB is 
imperative to treating these debilitating and 
costly diseases [8].
IN delivery offers several advantages over oth- 
er routes of administration: It is relatively non-
invasive, it avoids first-pass metabolism and 
its side effects can be minimized since other 
healthy organs are not exposed to the thera-
peutic compound [4]. Because of its non-inva-
sive nature, there is a reduced risk of infection 
or disease transmission. Additionally, nasal 
spray formulations are easy to administer and 
can be performed at home by the patient. As 
with any route of delivery, however, there are 
challenges that must be overcome when using 
the nasal cavity for therapy delivery. Similar to 
the BBB, the nasal mucosal barrier poses IN 
delivery challenges, such as a physical bound-
aries provided by tight junctions, cellular mem-
branes and enzymes in the mucosal milieu. In 
addition, certain environmental substances, 
including pathogens and allergens, can irritate 
the nasal mucosa and full delivery of a drug 
may be impaired when a patient has an active 
upper respiratory infection. Mucociliary clear-
ance can also hinder the delivery of intranasally 
administered therapeutics. Thus, only a small 
percentage of the administered drug may arrive 
at the target site following IN delivery; so, a 
compound requiring relatively high concentra-
tions for therapeutic efficacy may not be an 
ideal candidate for this route.
Aside from its purported role as a promising 
route of drug delivery, the nasal cavity normally 
serves important roles in respiration and smell 
while also providing a protective barrier against 
environmental insults [9]. The nasal anatomy in 
animals can differ widely relative to humans. 
For instance, the ratio of surface area to lumi-
nal volume in the nasal cavity of a rat is very 
different from that in humans (i.e., rat is 3350 
mm2/cm3 and human is 820 mm2/cm3) [10]. 
The relatively larger dedication of olfactory 
mucosa to smell in rodents allows a particu- 
larly strong model for IN delivery, but a lower 
contribution of olfactory mucosa to smell in 
humans poses a challenge when interpreting 
drug efficacy results from rodent data. The 
anterior vestibule, the respiratory region and 
the olfactory region serve as three different 
anatomically distinct areas in the nasal cavity 
and only the respiratory and olfactory regions 
are thought to contribute to drug delivery 
(Figures 1 and 2) [9, 10].
The respiratory epithelium is the largest of the 
three areas, is located more anteriorly within 
the nasal cavity, and produces the majority of 
the mucus, which is an additional barrier that 
intranasally delivered drugs must overcome for 
CNS delivery [11]. Drugs that overcome muco-
ciliary clearance and make their way across the 
respiratory epithelium, such as naloxone and 
zolmitriptan, may be absorbed into the small 
blood vessels within the lamina propria, where 
they would avoid first-pass metabolism encoun-
tered with orally delivered agents, but would 
then still need to cross through the BBB from 
the systemic circulation [12]. The lamina pro-
pria of the respiratory epithelium also contains 
a high surface area of branches of the trigemi-
nal neuron which, along with a multitude of 
small blood vessels, that provides a significant 
perineuronal and perivascular pathway for ther-
apeutics to enter the brain [4, 13-15]. For 
instance, Lochhead et al. used ex vivo fluores-
cence imaging (FLI) to show that bulk flow 
within the perivascular space of cerebral blood 
vessels contributes to the rapid central distri-
bution of small-molecule, fluorescently labeled 
dextran tracers after IN administration in anes-
thetized adult rats [15]. Labeled macromole-
cules, such as interferon gamma [16], insulin-
like growth factor [14], and most recently insu-
lin [17], also demonstrated rapid uptake into 
the brain and cerebral spinal fluid (CSF) spa- 
ces along the trigeminal route following IN 
administration.
The olfactory epithelium is the most posteriorly 
located epithelium of the nasal cavity (Figures 
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1 and 2), and is structurally different from the 
respiratory epithelium since it contains bipolar 
primary receptor neurons necessary for our 
sense of smell [18, 19]. The olfactory epitheli-
um overlies the cribriform plate and biopsy 
studies of humans indicate that the olfactory 
region may cover more of the nasal cavity than 
previously thought, extending to involve the 
middle turbinate (Figures 1 and 2) [9, 20]. Like 
the respiratory epithelium, the olfactory neuro-
epithelium sits atop a highly cellular lamina pro-
pria that contains the axon fascicles as well as 
Bowman’s glands, blood vessels, and connec-
tive tissue (Figure 3) [11]. However, the olfac-
tory epithelium also contains the olfactory 
Intranasal therapies
The various IN therapies that have been 
attempted and published are extensive. The 
current review provides only examples to give 
a flavor of intranasally delivered therapies. For 
a more detailed description specific to thera-
pies, the reader is referred to the following 
reviews by Fortuna et al. [22], Erdő et al. [23] 
and Corrigan et al. [24]. Although more often 
for systemic or local treatment, examples of 
therapies currently used clinically through the 
IN route include nasal sprays for allergic rhi- 
nitis (Azelastin Hydrochloride: Astelin, Meda 
Pharmaceuticals, Inc.), the common cold (Oxy- 
metazoline: Afrin, Merck and Co, Inc), vaccines 
Figure 1. The human nose-to-brain anatomy. In humans, the nasal cavity 
contains three major regions based on epithelial type. The first most ante-
rior vestibule (dark yellow), is comprised of squamous epithelial cells and 
does not play a significant role in drug absorption/uptake. Just posterior to 
the anterior vestibule is the respiratory epithelium (yellow). Drugs (green ar-
rows) absorbed across the respiratory epithelium can be deposited into the 
lamina propria where they gain access to an extensive pathway to the brain 
along the branches of the trigeminal nerve. Drugs can travel intraneuronally 
or in a perineural and perivascular distribution to enter the brain via the tri-
geminal ganglion (red) and brainstem (red). Finally, posteriorly and dorsally 
lies the olfactory epithelium (bright yellow), which houses the olfactory neu-
rons (blue), and is situated at the posterior and dorsal aspect of the nasal 
cavity. These neurons send cilia into the nasal cavity lumen. Drugs can be 
absorbed into the olfactory receptors or traverse the olfactory epithelium to 
gain access to the olfactory bulb by transcellular or perineuronal/perivas-
cular routes within the lamina propria. From the olfactory bulb (blue), drugs 
(purple arrows) gain access to the brain (pink).
receptor neurons and olfacto-
ry ensheathing cells, which 
can serve as a means of di- 
rect intra-neuronal transport 
into the olfactory bulb of the 
brain. This direct transport is 
made possible if the cilia aid 
in cellular uptake of the thera-
py or provide an additional 
highway to the brain CSF spac-
es. The cilia also provide a 
similar highway along exten-
sive perivascular and perineu-
ronal spaces found with the 
trigeminal system within the 
lamina propria. The classically 
cited example of direct neuro-
nal transport is wheat-germ 
agglutinin conjugated to hor- 
seradish peroxidase, which 
was visible in neuronal axons 
and the olfactory bulb follow-
ing IN delivery in mouse, rat 
and squirrel monkey [21]. 
However, intraneuronal trans-
port is slow with studies indi-
cating brain entry via the 
olfactory nerve taking 1.5-6 
hours and even longer via the 
trigeminal nerve, taking from 
17-56 hours [3]. Since several 
studies have confirmed rapid 
nose-to-brain delivery within 
minutes, the intra-neuronal 
pathway is probably not the 
primary route.
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(FluMist Quadrivalent, MedImmune, LLC), and 
others. Agents currently undergoing clinical tri-
pounds, such as nucleic acids and peptides/
proteins. We also discuss two additional cate-
Figure 2. Rat nose-to-brain anatomy. The nose-to-brain anatomy of the rat is 
similar to the human with a few differences. Compared to the human, the 
rat nasal cavity has a relatively greater surface area in the olfactory system, 
making it an ideal animal model for studying IN delivery. The rat nasal cavity 
consists of the anterior vestibule (dark yellow), respiratory epithelium (yel-
low), transitional epithelium and olfactory epithelium. Drugs (green arrows) 
gain access to the brain along the olfactory and trigeminal pathways, similar 
to human IN delivery.
Figure 3. Olfactory nasal mucosa. The olfactory epithelium is mostly com-
prised of olfactory receptor cells and sustentacular support cells. Deep to 
the olfactory epithelium is the lamina propria (pink), which contains blood 
vessels, lymphatics and abundant branches of the trigeminal sensory neu-
rons. Compounds deposited into the lamina propria can travel in a peri-
neural, perivascular or perilymphatic manner to access the brain (orange). 
The axons of the olfactory cells traverse the lamina propria and form nerve 
fascicles, called the fila olfactoria. Olfactory ensheathing cells (green) pass 
through the cribriform plate (yellow) along with the olfactory nerve axons. 
The olfactory neuron axons synapse in olfactory bulb with second order neu-
rons that then travel to other parts of the brain.
als, many of which take ad- 
vantage of the nose-to-brain 
route, include IN insulin for 
memory (NCT02758691), po- 
st-traumatic stress disorder 
(PTSD) (NCT04044534), mo- 
od disorders [25], and Alzhei- 
mer’s disease [26, 27]; IN 
glutathione for Parkinson’s 
disease (NCT01398748) [28]; 
IN oxytocin for autistic spec-
trum disorder [29, 30], Pra- 
der-Willi syndrome [31], att- 
ention-deficit/hyperactivity di- 
sorder (ADHD) [32] dementia 
[33], and schizophrenia; IN 
dexmedetomidine for seda-
tion of patients with autism 
spectrum disorder (NCT035- 
97477); IN fentanyl for cancer 
pain management (NCT009- 
94760); nerve growth factors 
for stroke (NCT03686163) 
and IN neuropeptide Y for 
PTSD (NCT01533519) [34]. 
Clinical trials of IN delivery are 
often focused in pediatrics 
because of the relatively gr- 
eater ease of IN administra-
tion compared to intravenous 
(IV) delivery and better patient 
comfort for pediatric patients. 
These include dexmedetomi-
dine for IN anesthesia (NCT0- 
3597477), IN ketorolac for 
pain (NCT02297906), and mi- 
dazolam for anti-anxiety (NCT- 
03635398). In addition to 
clinically approved drugs, the 
number of compounds under-
going experimental evaluation 
using the IN route in animal 
models is extensive and be- 
yond the scope of this review.
Therapeutic compounds deliv-
ered intranasally vary widely 
and each type of therapy has 
important challenges to con-
sider. In this review, we delin-
eate small molecules which 
are less than 900 Daltons 
from macromolecular com-
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gories: Nanosystems, including nanoemulsions 
(NEs) and nanoparticles (NPs), as well as thera-
peutic stem cells [35]. While all of these cate-
gories could be adapted to serve as theranostic 
agents, nanosystems and cellular therapies are 
particularly suited for this emerging concept, 
which combines therapy with diagnostic infor-
mation. Typically, nanosystems and cells have 
the greatest potential to adapt to become ther-
anostic agents. It should be noted, however, 
that not every theranostic agent is in the form 
of a nanosystem.
Small molecules
Small-molecule drugs are among the most 
common intranasally delivered therapies ad- 
ministered to humans because of their small 
size (less than 900 Da), which allows for rapid 
diffusion across cell membranes. Examples of 
clinically approved small molecules include 
anesthetic agents [36] as well as drugs that 
treat migraines [37], treatment-resistant de- 
pression [38], seizures [39], pain modulation 
[40, 41] and antidotes for drug overdose (i.e., 
naloxone) [42]. More experimental examples at 
the preclinical level include morphine and oxy-
codone for the reduction of intentional drug 
abuse [43, 44] and doxylamine in subjects 
with sleep impairment [45]. Since many small 
molecules are already approved for human use 
via topical, enteric or IV routes of administra-
tion, the regulatory burden for approval of IN 
delivery of small molecules is small [22]. 
However, most small molecules that can be 
used intranasally can also be delivered orally. 
In addition, many of the above-listed small mol-
ecules may utilize the nose-to-brain route to 
some extent, but the majority is likely to become 
systemically available following absorption 
across the nasal membrane barrier [46].
Nose-to-brain delivery of drugs occurs through 
a variety of different pathways; therefore, to 
optimize a small molecule for maximum deliv-
ery, it is important to tailor the molecule to trav-
el through any of the possible pathways rather 
than focus on any one [47]. Designing the best 
small molecule would involve balancing a vari-
ety of factors including hydrophilicity, polarity, 
charge, size and molecular interactions. Mucin, 
which is a glycoprotein constituent of mucus, 
has both hydrophobic and hydrophilic compo-
nents. While hydrophilic drugs are very soluble 
in mucus, leading to high clearance, extremely 
hydrophobic agents may interact with the 
mucus and fail to reach the nasal cavity [3, 22]. 
To achieve the highest probability of transport, 
a drug needs to exhibit moderate hydrophilic 
properties to minimize hydrophobic interac-
tions with the mucus and maintain the ability to 
be dissolved in aqueous medium, all while 
avoiding clearance. Molecules that are polar 
tend to have low bioavailability since they are 
prone to clearance or decomposition by nasal 
enzymes [22]. In terms of charge, mucin is neg-
atively charged; so, to minimize electrostatic 
interactions that would cause drug entrapment 
within the mucous, the drug needs to be neu-
tral or slightly negative at physiological pH [3]. 
While small molecules are generally not inhibit-
ed via size restraints, it is necessary to design 
these molecules in a way that limits potential 
molecular interactions that would trap them in 
the nasal mucosa for clearance and prevent 
absorption across the mucosa [48].
Macromolecular agents
IN delivery provides a viable route to the CNS 
for macromolecular agents if they can over-
come the anatomic and functional impedi-
ments of the nasal mucosal barrier. Examples 
of macromolecular agents include most drugs 
that are larger than 900 Da by molecular 
weight, but more specifically include agents 
that are not likely to be absorbed following oral 
delivery such as peptides, proteins, and nucleic 
acids. These agents are commonly called bio-
logics, which are considered a collection of 
macromolecular compounds with a high poten-
tial for therapy. Most proteins [22] and even 
therapeutic plasmids [49] and viruses [50] 
would fall into this category. Therapeutic neuro-
peptides belong to a class of small peptides. 
They are promising for IN drug delivery for CNS 
applications because of their decreased mo- 
lecular weight compared to larger proteins and 
macromolecular compounds. A good example 
in this group is oxytocin, which has been stud-
ied extensively as a psycho-modulator of sev-
eral cognitive responses and social interac-
tions [51, 52] and has been used in clinical tri-
als to treat mental disorders [53-55].
Macromolecules are prone to the same issues 
as small molecules since these, too, must tra-
verse the aforementioned barriers and abide 
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by optimization guidelines. Compared to small 
molecules, macromolecular agents are much 
more sensitive to size and, as the molecular 
weight increases, the absorption rate decreas-
es [48]. Given the limitations encountered with 
delivering small molecules and macromole-
cules across the nose-to-brain barriers, several 
absorption-enhancing materials are being in- 
vestigated and developed, including cell-pene-
trating peptides (i.e., penetratin [56, 57]), 
agents that open the tight junctions between 
cells (i.e., chloramphenicol acetyltransferase 
and matrix metalloproteinases [58]), and even 
agents that reversibly destroy the most sup- 
erficial layer of the nasal mucosa (i.e., methim-
azole [59]). However, with the implementation 
of enhancers, there is a risk of a leaky BBB 
and a risk of CNS infection, potentially leading 
to brain edema [3]. In addition, macromole-
cules are subject to other challenges such as 
higher susceptibility to enzymatic degradation, 
from lower permeability and shape restraints 
[22]. Furthermore, it was found that linear mol-
ecules seem to have lower absorption than 
cyclic molecules [22]. The optimization of small 
and large molecules was outlined by Kumar et 
al. [48]. Some characteristics to look for include 
therapeutic effects at lower volumes, appropri-
ate nasal absorptive characteristics, minimal 
nasal irritation, higher drug stability, and mini-
mized odors or other comfort deterrents with 
the therapy [48].
Nanosystems
Despite the potential advantages of IN delivery 
to circumvent the BBB, most small-molecule 
and macromolecule therapies in solution must 
still overcome several obstacles in transit to 
the brain or CSF spaces. It is estimated that 
98% of low-molecular-weight molecules and 
100% of high-molecular-weight macromole-
cules fail in entering the CNS due to physio- 
logical and physiochemical challenges [48, 
60]. The extremely low bioavailability of these 
molecules challenges their use intranasally. 
However, concentration levels can be further 
manipulated by nanotechnology-based sys-
tems, nanosystems. Specific examples that 
can be grouped more broadly into nanosystems 
would include nanogels, dendrimers, nanosus-
pensions, NEs, and NPs, to name a few [48, 
61]. Drug-loaded nanosystems present various 
advantages that have potential to overcome 
the aforementioned challenges. These include 
improved endothelial permeability and extra- 
vasation, enhanced interstitial diffusion and 
decreased clearance or trapping by phago-
cytes. Additionally, nanosystems can be deco-
rated with disease-specific ligands that target 
biomarkers of interest, thereby improving th- 
eir biodistribution profile and minimizing toxi- 
city to healthy tissues. Incorporating CNS dru- 
gs into nanosystems can also preserve the 
pharmacological action and physicochemical 
integrity of the drugs and reduce their dilution 
with body fluids. These advantages can signifi-
cantly improve the safety profiles of CNS drugs 
and increase their maximum tolerated doses 
(MTDs). Overall, to justify an agent’s delivery 
via a nanosystem, its incorporation must over-
come the limitations associated with free drug. 
Furthermore, drugs that are quickly cleared 
need to have increased absorption and the 
nanosystem must protect the drug from enzy-
matic degradation in the nasal cavity. Strong 
drug candidates would include low water solu-
bility, instability, slow onset of action, and those 
requiring high dosages that create systemic 
side effects [60]. Optimal nanosystems would 
remain less than 200 nm as the diameter of 
olfactory axons ranges from 100 nm to 700 nm 
and the mesh size of mucin ranges from 20 nm 
to 200 nm [3, 60]. To sum up, the benefit of 
using a nanosystem as a drug carrier and/or 
solubilizer is the ability to modify and fill in any 
weaknesses associated with the delivery of 
free drugs. There are a variety of different 
materials available to complete this.
Further optimization methods address the chal-
lenges discussed above. Each nanosystem has 
distinct advantages, but NPs and NEs will be 
described in brief specifically, outlining their 
role in IN delivery and imaging. For a more 
detailed information regarding nanosystems, 
the reader is referred to reviews from Kumar et 
al. [48], Patra et al. [62], and Chavda [61].
NPs are compact particles with diameters 
ranging from 1 to 1000 nm [48]. They can be 
fabricated by a variety of procedures inclu- 
ding solvent evaporation, ionic gelation, or pre-
cipitation [61, 63]. NPs may be composed of 
biodegradable and non-biodegradable constit-
uents and can be categorized as polymeric, 
polymeric micelles, liposomal, and inorganic, 
among others [64]. Polymeric NPs are often the 
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simplest type, utilizing single polymer chains. 
Alteration of polymer molecular weights allows 
fine tuning of drug release kinetics. Polymeric 
NPs can be fabricated with a variety of differ- 
ent methods including dispersion of polymers, 
polymerization of monomers, and ionic gela- 
tion [65]. Polymeric micelles are self-assem-
bled polymeric amphiphiles that can deliver 
hydrophobic drugs, though there have been 
studies utilizing them to deliver hydrophilic 
imaging agents which were loaded into mice- 
lle’s core through polymer-metal complex for-
mation [66]. Liposomal NPs are also self-
assembled via methods such as nanopreci- 
pitation [67], thin-film hydration and extrusion 
[68], and electrospinning [69] and can encap-
sulate both hydrophobic and hydrophilic drugs 
and imaging agents. Finally, inorganic NPs 
offer advantages for both imaging and therapy 
as they contain materials such as iron oxide, 
gold and silica, among others. Gold NPs, in par-
ticular, are useful as they have also been stud-
ied as radiosensitizers for cancer cells [70]. 
These are non-biodegradable and are very 
small, less than 100 nm. Several NPs are FDA 
approved for human use and are extensively 
outlined by Bobo et al. including polymeric NPs 
(Copaxone® and Eligard®), polymeric micelles 
(EstrasorbTM), polymer-protein conjugates (e.g., 
Peglntron®, Somavert), liposomal NPs (Mar- 
qibo®, Doxil®/Caelyx® and Onivyde®), and inor-
ganic NPs (Nanotherm®, Ferrlecit®, and Fer- 
ahemeTM) [64]. One example of current rese- 
arch is polycaprolactone polymer NPs prepa- 
red by nanoprecipitation. They are being inves-
tigated for the nose-to-brain delivery of me- 
latonin for the treatment of glioblastoma. 
Compared to free drug, melatonin NPs had 
significantly improved therapeutic efficacy, 
reducing the amount of drug required [63]. 
Bioavailability of NPs has been a debatable 
subject as IN delivery poses the same physical 
and chemical barriers like other drugs; the 
difference is that NPs offer more chances to 
finely tune the delivery system [48]. Furth- 
ermore, there are general challenges such as 
macrophage recognition of surface moieties. A 
variety of mucoadhesive polymers are incorpo-
rated to extend adhesion time in the nasal 
cavity, thereby preventing clearance. These 
include chitosan, alginates and cellulose [22]. 
Increased adhesion time as a mean to promote 
increased therapy remains controversial. On 
one side, increased adhesion prevents trans-
port to the brain. On the other, increased adhe-
sion prevents clearance and increases the 
chance of endocytosis [3]. Other challenges 
include premature release of drugs, toxicity and 
achieving desired dose requirements [61].
NEs are nano-sized globules that are biphasic, 
containing two immiscible liquids (water/oil) 
and a variety of surfactants and co-surfact- 
ants [71]. Some commercially available NEs, 
not specific to nose-to-brain delivery, include 
Diazemuls®, Lipuroetomidate® and Diprivan®, 
etc. Unlike NPs, there is no distinct boundary 
of each droplet; however, the globule is typi- 
cally known to have sizes of 100-300 nm or 
less [60]. NEs are either oil-in-water (O/W) or 
water-in-oil (W/O) emulsions fabricated by high 
energy (ultrasonication/homogenization) or low 
energy (phase inversion by temperature/com-
position changes) techniques [60]. However, to 
our knowledge, only an O/W emulsion is used 
for IN administration of drugs. NEs interact 
directly with the aqueous environment via 
Brownian motion of the droplets [48]. NEs, like 
NPs, allow the transport of hydrophobic drugs 
into the brain. For example, saquinavir is an 
anti-HIV drug, but its water insolubility ren- 
ders it a strong candidate for delivery via a NE. 
NEs showed an increase in permeation into 
the brain compared to free drug [60]. Another 
study by Colombo et al. analyzed the effects of 
incorporating chitosan into NEs [72]. Chitosan 
is heralded in NEs for its ability to act as a 
mucoadhesive to decrease nasal clearance 
[71]. A NE containing kaempferol was made 
with and without conjugation to chitosan for 
the treatment of glioma. It was found, in an ex 
vivo analysis, that NEs conjugated to chitosan 
significantly increased permeation across the 
mucosa because of the electrostatic interac-
tion of positively charged chitosan and nega-
tively charged mucosal layers, while also sig- 
nificantly increasing the amount of drug deliv-
ered to the brain [72]. Mucoadhesives appear 
to be quite critical in avoiding NE clearance 
and their use optimizes drug delivery [71]. 
Uniquely, NEs use a high concentration of sur-
factants that can be chosen from a list of gen-
erally regarded as safe (GRAS) agents including 
polyethylene glycol (PEG) 8 stearate, PEG 400, 
polysorbate 20 and propylene glycol, to name a 
few [61, 71]. Such surfactants can provide a 
fluidizing effect on the barrier endothelial cells, 
promoting drug permeability within the olfacto-
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ry and trigeminal pathways [60]. Despite their 
advantages, those surfactants need to be 
monitored for toxicity with repeat dosages. 
Furthermore, both NPs and NEs are subjected 
to scale-up challenges. In a laboratory setting, 
these systems are made using specific material 
amounts in a specific order, which makes their 
translatability to industry a challenge.
Cellular therapies
IN delivery of stem cells to the brain overcomes 
the certain challenges associated with brain 
drug delivery and is highly amenable to ther-
anostics. Multiple studies have confirmed the 
localization of various stem cells in the brain 
following IN delivery, including mesenchymal 
stem cells (MSCs), neural stem cells (NSCs) 
and pluripotent stem cells [73, 74]. MSCs were 
delivered to the brain via the IN route, success-
fully treating animal models of neurodege- 
nerative diseases, including Parkinson’s dis-
ease, Alzheimer’s disease and Huntington’s 
disease [75-77]. MSCs have also been deliv-
ered intranasally for the treatment of stroke 
[78, 79], including neonatal hypoxia-ischemia 
[80, 81]. In addition, MSCs delivered via nasal 
application imparted therapeutic efficacy 
when expressing tumor necrosis factor (TNF)-
related, apoptosis-inducing ligand in a mouse 
model of human glioma. The increased overall 
survival was even higher when the mice had 
been irradiated [82]. The irradiated mice 
showed higher levels of CXCL12, a lymphatic 
chemokine, which is possibly related to the 
mechanism of migration of those cells [83]. 
Although radiotherapy is a highly effective tool 
for the treatment of brain cancer, it also causes 
detrimental effects in surrounding healthy tis-
sues, leading to pernicious neurocognitive 
side effects. A novel strategy to mitigate the 
negative effects of radiation in brain tumor 
treatment involved IN administration of hu- 
man MSCs, which promoted brain injury repair 
and improved neurological function following 
brain irradiation in mice [84]. Stem cells have 
become carriers of oncolytic agents or drugs 
due to their capability to target brain tumors 
when the stem cells and tumor cells express 
specific cell adhesion molecules. For instance, 
CXCR4-enhanced NSCs delivered an oncolytic 
virus to glioma and extended survival of ani-
mals when they received concomitant radio-
therapy [85]. Moreover, neural stem/progenitor 
cells (NSPCs) displayed a rapid, targeted tumor 
tropism with significant accumulation at the 
intracranial glioma site within 6 hours after IN 
delivery. This peaked at 24 hours and rema- 
ined at this level for up to five days. Currently, 
two clinical trials are assessing IN delivery of 
stem cells in the brain. One is recruiting to 
evaluate the use of autologous bone marrow-
derived stem cells (BMSC) to improve cogni- 
tive function (NCT03724136). Another is also 
recruiting to study the use of autologous BMSC 
and its transfer to the vascular system and 
inferior 1/3 of the nasal passages in order to 
determine if such treatment will provide 
improvement in neurologic function for patients 
with a broad spectrum of neurologic conditions 
(NCT02795052). Overall, cellular therapies are 
an emerging therapy that may offer many ben-
efits for IN delivery.
Theranostics
The development of a single platform for the 
simultaneous delivery of therapeutics and 
diagnostic imaging agents for pretreatment 
planning, real-time tracking/monitoring and/or 
posttreatment assessment provides the basis 
for the emerging field of theranostics [86]. 
Molecules such as metaiodobenzylguanidine 
(MIBG) containing iodine-131 (131I) and io- 
dine-123 (123I), somatostatin peptide analogs 
labelled with lutetium-177 (177Lu) and prostate-
specific membrane antigen (PSMA) labelled 
with 123I, 131I, gallium-68 (68Ga), 177Lu and yttri-
um-90 (90Y) have been used as theranostic 
materials in nuclear medicine [87, 88]. Also, 
radioactive 131I is used to simultaneously im- 
age and treat thyroid diseases [89]. In general, 
direct imaging of small-molecule and macro- 
molecular therapies following IN delivery in 
vivo is difficult to do since the addition of an 
imaging tracer runs the risk of interfering with 
drug binding site, thereby altering therapeutic 
efficacy. Imaging labels directly conjugated 
onto the therapeutic agent may also negatively 
alter biodistribution and pharmacodynamic/
pharmacokinetic profiles. Regardless, direct 
labeling of drugs would benefit from in vivo 
imaging to better understand the ultimate fate 
of therapies after delivery, which includes the 
route of transit from nose-to-brain. When devel-
oping therapies that utilize nanosystems or 
cells, labeling agents for in vivo imaging 
becomes more feasible, albeit still technically 
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challenging. A recent NP-based drug delivery 
system was formulated for the treatment of 
glioblastoma by Sukumar et al.; it provides a 
comprehensive example of the multiple func-
tions NPs can have. Briefly, gold-iron oxide 
NPs loaded with microRNAs for IN delivery 
were produced to provide a multi-functional 
theranostic capability for the treatment of glio-
blastoma. These NPs were coated with β-cy- 
clodextrin-chitosan (CD-CS) hybrid polymer for 
the co-loading of the microRNAs. Finally, the 
NPs were decorated with PEG-T7 peptides to 
specifically target glioblastoma cells. In vivo 
analysis showed that these multi-functional 
NPs provided tumor sensitization, via the 
microRNAs, to the standard-of-care treatment, 
temozolomide, improving overall survival. Be- 
cause of the gold-iron oxide component, the 
IN delivery of the NPs was monitored via 
T2-weighted magnetic resonance imaging (MRI) 
[90].
Intranasal imaging
In humans, IN imaging studies have thus far 
been limited mostly to MRI, positron emission 
tomography (PET) and single-photon emission 
computed tomography (SPECT), with MRI being 
the most extensively utilized modality. Gamma 
scintigraphy, to our knowledge, has been used 
clinically in the context of IN imaging in one 
instance. Preclinical studies that utilize imaging 
offer a great deal of information about the fate 
of the delivered therapeutic and/or disease 
progression, which would enable the efficacy of 
novel IN therapies and their potential for clini-
cal translation. So far, preclinical imaging stud-
ies have not only utilized MRI, PET and SPECT 
but also gamma scintigraphy as well as bio- 
luminescence imaging (BLI) and fluorescence 
imaging (FLI). Ultrasound imaging, however, 
has not yet been used for IN imaging by virtue 
of the difficulties associated with transmitting 
and receiving acoustic waves across osseous 
structures using diagnostic ultrasound trans-
ducers in the clinical megahertz ranges. Ne- 
vertheless, ultrasound waves can be focused 
using specialized therapeutic focused trans-
ducers in order to enhance transmission and 
enable therapeutic benefits for IN drug deliv-
ery; this emerging approach, which is known as 
focused ultrasound-mediated drug delivery, will 
be briefly discussed later in this Review. A few 
CT studies have been used in humans and ani-
mals, mostly to study nasal anatomy and nasal 
flow dynamics. Combined PET and MR has per-
haps the highest future potential for the ass- 
essment of the nose-to-brain route of drug 
delivery since they can combine both the high 
quantitation and sensitivity of molecular imag-
ing with the high tissue contrast and spatial 
resolution of MRI. However, very few studies 
have been performed to date using this dual-
modality approach which enables understand-
ing of in vivo biological processes at a funda-
mental level. In subsequent paragraphs, we 
review each imaging modality and its contribu-
tion to understanding IN delivery from both a 
preclinical and clinical perspective.
Magnetic resonance imaging
MRI is a powerful, non-ionizing imaging tech- 
nology that utilizes a strong magnet (typically 
0.5-3 tesla for humans and up to 21.1 tesla 
for small animals) to produce three-dimension-
al detailed anatomical images [91]. MRI has 
revolutionized medicine because of its ability to 
generate high spatial resolution images and 
exquisite soft tissue contrast (Table 1). In 
humans, it is used for disease detection and 
therapy monitoring. MRI signals are produced 
through the process of resonance using radio-
frequency (RF) coils, which include a transmit-
ter and receiver. The RF transmitter coils gener-
ate a secondary magnetic field (B1) that is per-
pendicular to the main magnetic field (Bo), 
whereas the RF receiver coils detect the result-
ing MR signal. The transmitter and receiver 
functions are often separated in order to maxi-
mize the signal-to-noise ratio (SNR) of a given 
imaging sequence [92]. Image contrast in MRI 
is mainly based on inherent properties of bio-
logic tissues; these include proton content (i.e., 
1H spin density), longitudinal recovery time (T1) 
as well as transverse relaxation times (T2 and 
T2
*) of 1H nuclei [93, 94]. MRI of the brain allows 
a high level of detail and with the use of higher 
magnetic fields, animals as small as mice can 
be imaged. Although MRI is widely available 
clinically, only certain centers of research have 
more sophisticated MRI capability at the small-
animal, preclinical level. Multimodality, multipa-
rametric imaging in small animals is even less 
frequently available. Regardless, these tech-
nologies are continuously evolving to reduce 
the costs and scan times as well as improve 
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Table 1. Comparison of imaging modalities utilized in intranasal delivery of therapeutics to the brain
Imaging modality Strength Weakness Spatial resolution Sensitivity
MRI -No ionizing radiation 
-Excellent soft-tissue contrast 
-Superior spatial resolution with multiplanar imaging capabilities 
-Very versatile and widely available for both preclinical and human imaging studies 
-Can utilize magnetofection
-Expensive 
-Gd-based contrast agents can be toxic 
-Susceptible to patient movement-induced image artifacts 
-Relatively slow patient throughput 
-Some patients may experience claustrophobia 
-Safety hazards for patients with implanted medical devices 
-Possible thermal injuries in the body and hearing issues
+++++ ++
CT -Provides detailed images of many tissue types, including osseous tissue 
-Can image soft tissue, bone and blood vessels simultaneously 
-Relatively inexpensive and fast compared to MRI 
-Unlike MRI, patients with implanted medical devices are safe inside a CT scanner 
-CT is less sensitive to patient motion than MRI 
-Can complement PET or SPECT, both clinically and preclinically 
-Micro-CT is available for laboratory use
-Involves ionizing radiation 
-Patients may experience adverse reactions to contrast agents 
-Generally, not recommended for pregnant women
++++ +
Gamma Scintigraphy -Easy to use, fast and inexpensive 
-Provides functional information 
-Can be used in drug discovery and development to facilitate pharmacokinetic/pharmaco-
dynamic and biodistribution studies 
-Higher spatial resolution than SPECT
-Involves ionizing radiation 
-2D images with poor spatial resolution compared to MRI or CT 
-no CT or MR combination for anatomy overlay 
-Lower detection sensitivity compared to SPECT 
-Requires physical collimators that reject photons that are 
not within a very limited angular range, thereby decreasing 
sensitivity compared to PET
+++ ++
SPECT -Enables noninvasive visualization of biodistribution of radiolabeled tracers for diagnostic 
applications and assessment of treatment efficacy 
-Utilizes common radiopharmaceuticals, like Tc-99m, that are widely available 
-Relatively inexpensive -Can be employed in a dual-modality system (SPECT/CT) 
-Can do multi-isotope imaging (i.e., multi-radioisotope resolution) 
-Can allow for widening observational time window of imaging due to the longer half-life of 
single photon emitters
-Involves ionizing radiation 
-Less quantitative than PET 
-Requires collimation which introduces noise, decreases sensi-
tivity, and increases san time 
-Relatively poor spatial resolution compared to MRI or CT
++ +++
PET -More sensitive than SPECT (two to three orders of magnitude) 
-Many radiopharmaceuticals are available 
-Short-lived radionuclides used in PET improve detection sensitivity 
-Quantitatively accurate 
-Most often as a molecular imaging modality combined with CT and most recently with MRI 
-Micro-PET is available for animal studies
-Involves ionizing radiation 
-Expensive 
-Requires complex equipment 
-Quantitative data analysis depends on specialized software 
tools 
-Relatively poor spatial resolution compared to MRI or CT
++ +++++
Optical -Safe, sensitive, widely available, inexpensive with high spatial resolution 
-Nonionizing radiation 
-Fast (e.g., multiple animals can be imaged at once, reducing imaging operation time and 
costs) 
-Can be used to monitor disease progression, therapeutic efficacy and molecular processes
-Unusable for deep tissues 
-Cannot be performed non-invasively in vivo on brain easily 
secondary to skill
++++++ ++++++
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software interfaces for the use of MRI in both 
the clinical realm and the investigational set-
ting in both humans and animals.
Contrast agents utilized in MRI include gadolin-
ium-based contrast agents (e.g., gadolinium-
diethylenetriamine pentaacetic acid (Gd-DTPA)) 
and iron-containing agents. Gadolinium-based 
agents allow for contrast enhancement and 
image brightening by shortening T1 times of 
hydrogen nuclei in contrast agent-containing 
biologic tissues, further delineating regions of 
interest (e.g., tumors). Iron, on the other hand, 
is visualized using T2- or T2
*-weighted MRI 
parameters by shortening T2 times and induc-
ing a hypointense signal. Moreover, by utilizing 
fluid- or fat-eliminating techniques (e.g., FL- 
AIR, STIR, and T2 fat saturation), the pathology 
can often be better visualized. Certain sequenc-
es, including gradient recalled echo (GRE) and 
susceptibility-weighted imaging (SWI), detect 
hemorrhage or calcification through what is 
known as a blooming artifact. In addition to 
static imaging, MRI can be used to collect 
dynamic information such as with various per-
fusion techniques, which are more commonly 
utilized in stroke and tumor imaging. Examples 
of perfusion techniques include dynamic sus-
ceptibility contrast, dynamic contrast enhance-
ment and arterial spin labeling. Another MRI 
technique that can detect the diffusion of wa- 
ter through space is known as diffusion-weight-
ed imaging (DWI). DWI is the clinical workhorse 
for the detection of stroke and abscesses. 
Diffusion tensor imaging (DTI) is another diffu-
sion-related sequence which analyses the 
three-dimensional shape of the diffusion of 
water in space to generate an image. Similarly, 
functional MRI (fMRI) indirectly measures oxy-
gen utilization in certain resting states or acti-
vated brain regions to generate regional maps 
of brain activity.
In animals, MRI can be performed at baseline 
and following therapy to assess changes in the 
brain compared with the original baseline. 
Examples include animal models of brain 
tumors such as glioblastoma [59, 74, 83], 
stroke [95] autistic spectrum disorder [96], 
multiple sclerosis [97], and neuroinflammation 
[98]. Using DTI and metric fractional anisotropy, 
IN delivery of myelin oligodendrocyte glycopro-
tein (MOG35-55) was shown to ameliorate pro-
gression of disease and reduce brain damage 
in a mouse model of multiple sclerosis [97]. 
The neuroprotective peptide, NAP (part of the 
8 amino acids in NAPVSIPQ) also called davu-
netide (CP201), which is derived from activity-
dependent neuroprotective protein (ADNP) was 
pioneered by Dr. Gozes and her team. This 
promising agent has been shown to be neuro-
protective in numerous neurodegenerative ani-
mal models of disease, including Alzheimer’s 
disease, Parkinson’s disease, frontotemporal 
dementia and amyotrophic lateral sclerosis 
[96]. Most recently, the group demonstrated 
the neuroprotective effects of NAP augmented 
by the penetration enhancer chorabutanol in 
ADNP+/- mouse model of autistic-like ADNP 
syndrome. Using a 7-tesla MRI unit for in vivo 
imaging of seven eight-month-old mice, NAP 
protected against abnormal increases in DTI-
derived mean diffusion and fractional anisot-
ropy in the hippocampus in the ADNP+/- mice 
following IN delivery of NAP, demonstrating its 
translatability to clinical practice. In an inter- 
esting study, Zhang et al. utilized DTI-derived 
fractional anisotropy and other histologic tech-
niques to demonstrate a regenerative role of 
interleukin-4 (IL-4) beyond its known immuno-
regulatory functions in an experimentally in- 
duced middle cerebral artery occlusion mouse 
model [95]. IL-4-loaded liposomal NPs were 
administered intranasally at 1-7 days, 14 days, 
21 days and 28 days following middle cerebral 
artery (MCA) occlusion and was found, using in 
vivo DTI on a 9.4-tesla MRI system and histo-
logically, to improve white matter integrity. 
Long-term sensorimotor and cognitive deficits 
also improved in the IL-4 NP-treated group 
compared with vehicle-treated mice.
Direct localization of therapeutic agents in 
MRI have so far been limited to nanosystems 
and cellular therapies. For instance, a cholera 
toxin B subunit-derived NP was found in the 
hippocampus at one hour after IN delivery in a 
mouse [99]. By tagging the cholera B toxin 
NPs with Cy5.5 (an internal fluorescence pro- 
be that served as a model drug) and Gd3+ (an 
MRI contrast agent), 7-tesla MR images were 
obtained in vivo followed by ex vivo histologic 
and fluorescence microscopy of brain sections. 
Although the authors claimed that the cholera 
toxin could be a nanosystem for the treatment 
of Alzheimer’s disease and could target the hip-
pocampus, a therapeutic drug was not deliv-
ered and a mouse model of Alzheimer’s dis-
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ease was not utilized in this study [99]. In 
another study, MRI was utilized by Balyasni- 
kova et al., to demonstrate the localization of 
MSCs to the tumor site in an animal model of 
glioblastoma at 48 hours following IN delivery 
[83]. The MSCs were engineered to express 
TNF-related apoptosis-inducing ligand (TRAIL) 
on the cell membrane for improved therapeutic 
efficacy in an irradiated glioblastoma mouse 
model. Additionally, the MSCs were loaded with 
micron-sized paramagnetic iron oxides (MPIOs) 
and then delivered intranasally to the brains of 
irradiated and non-irradiated mice with glio-
blastoma. The mice were then imaged 48 
hours later with MRI utilizing a high-resolution, 
T2-weighted rapid acquisition with relaxation 
enhancement (RARE) spin-echo images and 
multi-slice, high-resolution, T1-weighted, fast 
low-angle shot (FLASH) gradient-echo sequ- 
ences (Figure 4). Importantly, the authors uti-
lized a clinically relevant imaging modality for 
the first time to demonstrate delivery of MSCs 
to the brain from the nose. More recently, 
Spencer et al. intranasally administered NSCs 
loaded with superparamagnetic iron oxide 
nanoparticles (SPIONS) with methimazole to a 
mouse model of glioblastoma [59]. The mice 
were imaged at 24 hours, 48 hours, and 120 
hours following NSC treatment using a 7-tesla 
Bruker MR scanner. The pre-treatment addition 
of methimazole delayed mucociliary clearance 
of the NSCs from the nasal cavity for 24 hours 
and amplified localization to the tumor site to 
a greater extent than without a pre-treatment 
methimazole administration. Another study 
demonstrated IN delivery of insulin in a rat 
model of moderate traumatic brain injury (TBI) 
by MRI, performed at days 3 and 9 post injury, 
to result in a significant decrease in hippocam-
pus lesion volume [100]. 18F-fluorodeoxyglu-
cose (18F-FDG) PET imaging was also perfor- 
med on days 2 and 10 to demonstrate reduced 
inflammation and decreased cerebral glucose 
uptake, which are additional attestations to the 
therapeutic efficacy of insulin in TBI following IN 
delivery in this same animal model.
Furthermore, IN delivery of the anti-inflammato-
ry and neuroprotective agent cyclosporine-A, 
contained within an oil-based, omega-3 fatty 
acid-rich flaxseed NE system, demonstrated 
therapeutic efficacy by inhibiting proinflamma-
Figure 4. High-resolution T1- and T2-weighted MRI of intranasally administered MSCs. (Adapted from Balyasnikova 
et al., 2014 with permission). High-resolution T1- and T2-weighted MRI of intranasally delivered MSCs, loaded with 
MPIOs, were visualized migrating to the brain of irradiated intracranial glioblastoma-bearing mice to a greater de-
gree than non-irradiated glioblastoma-bearing mice. Top two rows are in the coronal plane and bottom row is an 
axial plane. Red arrows point to dark signal representing the MPIOs.
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tory cytokines in lipopolysaccharide-induced 
rat model of neuroinflammation as compared 
to a similar solution formulation without NE 
[98]. The T1 MRI contrast agent gadolinium 
was complexed with the same NE system in 
place of cyclosporine-A. Using a 7-tesla MRI 
unit, the authors showed a higher uptake of the 
NE-gadolinium conjugate in major regions of 
the brain when dosed intranasally based on 
changes in T1 relaxation times. Since cyclosprin-
A does not appear to also have been included 
in the MR-imaged preparation, the results can 
only be used to indirectly imply that the 
cyclosprin-A also reached this location in the 
brain.
A novel theranostic application is to utilize the 
high magnetic force of MRI to guide magnetic 
therapeutic agents to the desired location in 
the brain, a term that has been described as 
magnetic transfection or magnetofection. For 
instance, in a mouse model of TBI, chitosan- 
and polyethyleneimine-coated magnetic mice- 
lles were evaluated as a potential MRI contrast 
agent using a reporter DNA delivered to the 
brain after mild TBI [101]. Magnetofection was 
also used to increase the concentration of the 
chitosan- and polyethyleneimine-coated mag-
netic micelles in the brain, suggesting the pos-
sibility of using these as theranostic delivery 
vehicles.
With regards to human imaging of IN delivery, a 
multitude of recent articles have been pub-
lished to demonstrate the effects of insulin and 
oxytocin on various CNS conditions (for a recent 
review of insulin, see Santiago and Hallschmid, 
2019 [102] and for recent reviews of oxytocin, 
see Ding et al. [103], De Cagna et al. [104], and 
Horta et al. [105]). IN insulin is predominately 
being studied as a modulator of metabolic con-
trol (i.e., obesity and diabetes) and memory 
(i.e., mild cognitive impairment and Alzhei- 
mer’s disease) [102]. Oxytocin, on the other 
hand, is being studied in categories that inclu- 
de stress and anxiety, metabolism and weight, 
social engagement and bonding and pain and 
inflammation [105]. In a study examining the 
effects of insulin on memory in Alzheimer’s 
patients, 3D MRI volumetry using 3D T1 volu-
metric magnetization prepared rapid gradient 
echo (MPRAGE) sequences correlated with 
improved cognition and daily function following 
IN delivery of insulin [106]. In particular, for 
patients who experienced improvement in their 
memory following IN delivery subregional brain 
MRI volumes of the middle cingulum, cuneus, 
hippocampus, superior frontal, and parietal 
regions, were higher in Alzheimer’s patients 
compared with normal patients. In another 
study, arterial spin labeling MRI perfusion was 
utilized to measure central insulin action in the 
brain following IN delivery in lean, overweight, 
and obese adults to identify brain regions 
affected by insulin resistance. Insulin action 
was selectively impaired in the prefrontal cor-
tex in 23 overweight and obese adults com-
pared to 25 healthy control patients, potentially 
by promoting an altered homeostatic set point 
and reduced inhibitory control contributing to 
an over-eating behavior [107].
Since insulin is one of the most extensively 
studied agents in clinical trials following IN 
delivery, an fMRI study was performed to 
assess three commercially available insulin 
nasal delivery devices [108]. fMRI revealed a 
significant decrease in regional blood flow in 
areas dense in insulin receptors in the intrana-
sally delivered insulin group compared to saline 
alone. Also, using fMRI, oxytocin (24 IU) or pla-
cebo was delivered intranasally to 15 healthy 
patients in a randomized, double-blind manner 
to affect the precuneus and amygdala, key 
brain regions in social cognition and introspec-
tive processing [109]. In the nasal oxytocin 
study, fMRI measuring amygdala activity 
showed that body dysmorphic patients had 
higher baseline resting state functional con-
nectivity compared to placebo, which was 
reversed by oxytocin IN delivery. fMRI identified 
highly detailed and specifically localized areas 
of functional connectivity between brain re- 
gions [110]. In a separate study in humans, 
perillyl alcohol was delivered intranasally for 
the treatment of glioblastoma and lower grade 
gliomas in patients also receiving surgery, 
radiotherapy, and chemotherapy. Perillyl alco-
hol was found to be safe and demonstrated 
anti-tumor activity as assessed by MRI and CT 
after six months of treatment [111].
Positron emission tomography
PET is a promising, highly quantitative and sen-
sitive imaging tool used in disease diagnosis as 
well as the prediction and assessment of thera-
py response [112]. Being a sensitive imaging 
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system, PET enables us to quantitatively under-
stand physiological processes and pathways 
within the body at a fundamental level. From a 
therapy standpoint, PET holds probably the 
greatest potential for the development of ther-
anostic agents. PET images depict the distribu-
tion of positron (β+ particle)-emitting radionu-
clides (e.g., fluorine-18 (18F), rubidium-82 (82Rb), 
oxygen-15 (15O), nitrogen-13 (13N), carbon-11 
(11C), zirconium-89 (89Zr), and copper-64 (64Cu)) 
in the body. Emitted positron moves within tis-
sue and deposits its kinetic energy. Upon meet-
ing a free electron in tissue, a mutual annihila-
tion occurs, producing two 511 keV gamma 
photons (511 keV is the energy equivalent to 
the rest mass of an electron or positron). These 
two photons are emitted back-to-back, propa-
gating outward from the site of annihilation 
180 degrees apart. Therefore, PET scanners 
detect a pair of 511 keV photons in what is 
called annihilation coincidence detection (ACD) 
in order to obtain projections of radioactivity 
distribution in the patient. With this approach, 
only simultaneous gamma rays are detected 
(with multiple rings of detectors surrounding 
the patient) and declared as events. A time 
interval (or time window), typically 2-20 nano-
seconds for modern scanners, set by the user 
determines whether two detected photons are 
declared as “simultaneous” [113].
The majority of PET systems are coupled to CT 
scanners (PET/CT systems), though there is a 
growing interest in PET/MRI systems recently 
for both clinical pre-clinical studies. By detect-
ing the biodistribution of radiopharmaceuticals 
in the body, PET studies enable the diagnosis of 
a wide array of clinical conditions, including 
cancer, dementia, epilepsy, Parkinsonism as 
well as cerebrovascular and cardiovascular 
diseases. There are many PET radiopharma-
ceuticals, with new radiotracers and their asso-
ciated ligands being developed extensively 
[114]. Clinically, the most widely used radio-
pharmaceutical is 18F-FDG, which is a glucose 
analog that detects elevated metabolism in the 
body [115]. 18F-FDG PET has also been utilized 
in the detection of malignant lesions, staging 
cancer patients as well as assessing tumor 
treatment response [113]. Typically, the results 
are reported in the form of a standard uptake 
value (SUV) which is calculated based on the 
time of injected dose, the patient or animal’s 
body weight and the radionuclide rate of decay. 
Advantages of PET include its high quantitation 
and sensitivity relative to other modalities and 
its ability to co-register with CT and MRI. For 
instance, compared to other radionuclide im- 
aging techniques (e.g., SPECT), PET enables a 
greater detection sensitivity over a given period 
of time with its relatively short-lived radionu-
clides. That is, because PET utilizes radionu-
clides with shorter physical half-lives compared 
to SPECT, greater activities can be injected in 
patients without an increase in the overall radi-
ation. However, PET has several limitations. 
The most important limitation is poor spatial 
resolution relative to MRI or CT (Table 1). PET 
also has a relatively high cost with complex 
equipment, requiring trained personnel and 
specialized software [116]. Radiation exposure 
is also a risk to patients [117]. With regard to 
FDG, one major limitation is that elevated 
metabolism detected by 18F-FDG is found in 
both normal and abnormal tissues which reduc-
es background to noise ratio. This is because 
there is a typically high baseline glucose utiliza-
tion in the brain. Pathologic entities that would 
have high metabolism include abnormal inflam-
mation, tumors, cardiovascular disease, and 
brain disorders including dementia, epilepsy, 
Parkinson’s disease, stroke, and TBI [118].
As described in the MRI section, 18F-FDG PET 
and MRI were combined to study the effects of 
IN insulin on cerebral glucose uptake, lesion 
volume, memory and learning, and inflamma-
tion using a controlled cortical impact (CCI) TBI 
model in rats [100]. A significant reduction in 
18F-FDG uptake was observed in the hippocam-
pus on PET imaging along with a significant 
decrease in the hippocampal lesion volume on 
MRI, indicating that IN insulin may be a viable 
therapy for TBI.
Orexin A (hypocretin-1) is one of two isoforms 
of endogenous neuropeptides produced in the 
hypothalamus that plays an important role in 
modulating the sleep/wake cycle, energy and 
homeostasis, appetite and feeding, drug ad- 
diction and cognition [119]. Orexin A can be 
delivered intranasally with good efficacy [120] 
and exerts a neuroprotective and anti-inflam-
matory effect against various CNS disease 
states [119]. Despite ample evidence that orex-
in A can be delivered to the CNS intranasally, 
Van de Bittner et al. was unable to demonstr- 
ate CNS delivery following IN administration of 
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a 11C-radiolabeled form of orexin A (11C-CH3-
Orexin A) compared with 11C-raclopride using 
PET/MR in either rats or non-human primates 
(Figure 5) [121]. Furthermore, in a safety and 
efficiency trial of a nasal vaccine against botu-
lism, PET imaging of the botulinum type A 
neurotoxin (BoHc/HA), labeled with 18F (i.e., 
18F-BoHc/A), did not demonstrate uptake into 
the cerebrum or olfactory bulb, despite being 
highly protective against botulism in non-
human primates [122]. Nevertheless, PET/CT 
followed by fusion with MRI was shown in a rat 
model to be feasible for pharmacokinetic stud-
ies using compartmental modeling following IN 
delivery of the 18F-FDG radiotracer [123]. The 
authors were able to generate a time-activity 
curve after acquiring the data in list-mode from 
0.5-30 minutes following IN delivery to demon-
strate regional differences in permeability of 
the radiotracer in the nasal cavity. The authors 
concluded that absorption and distribution of 
drug in the rat nasal cavity can be quantitated 
using PET imaging, but FDG was not detected 
in the brain after IN delivery. These results are 
similar to another report that assessed IN deliv-
ery of FDG in humans [124]. The reason for this 
may be saturation of local tissues since these 
too have glucose transporters that would 
sequester FDG and prevent more distant perfu-
sion for brain entry.
In a recent clinical trial, an increase in brain 
metabolic activity was found in patients with 
Alzheimer’s disease and mild cognitive impair-
ment after four months of IN insulin when 
imaged by PET following IV administration of 
18F-FDG [125]. There was no change in the pla-
cebo group. As mentioned earlier, another ther-
apy that is amenable to IN administration is 
Figure 5. PET/MR of 11C-CH3-Orexin A and 
11C-raclopride in the brain and nasal cavity after intranasal delivery to 
the neuroepithelium. (Reprinted from ref. 122. Copyright 2018 American Chemical Society) Comparison of 11C-
CH3-Orexin A and 
11C-raclopride uptake in rhesus macaque brain after intranasal administration. 11C-CH3-Orexin 
A (A) and 11C-raclopride (B) were administered using a device for intranasal delivery to the neuroepithelium. At 90 
minutes, 11C-CH3-Orexin A was not visible in the brain using PET/MRI, while 
11C-raclopride was readily visible in the 
basal ganglia.
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oxytocin. Oxytocin inhibits the amygdala, de- 
creases anxiety and modulates depression and 
autism when delivered intranasally. Using a 
radiolabeled partial antagonist to 5-hydroxy-
tryptophan-1 receptors and PET/MRI, Motto- 
lese et al. demonstrated in a randomized, dou-
ble-blind control in humans that oxytocin mo- 
dulates the serotoninergic system by regulating 
the 5-hydroxy-tryptophan-1 receptor network, 
providing an important mechanism of action for 
oxytocin in humans [126].
Naloxone (Narcan) is a life-saving medication 
that can rapidly reverse opioid overdose and is 
available in various forms of administration, 
including IN [127]. In a study demonstrating the 
advantages of in vivo imaging, quantitative 
localization of intranasally delivered naloxone 
was demonstrated in the brains of 24 healthy 
male adult human subjects using 11C-Carfen- 
tanil PET imaging combined with brain MRI 
(Figure 6) [128]. Rapid mu opioid receptor 
occupancy of naloxone following IN delivery 
was demonstrated directly for the first time in 
this study and fit well with the rapid (< 5 min-
utes) reversal of opioid overdose. The authors 
proposed that naloxone’s rapid onset and half-
life occupancy of mu opioid receptors of about 
100 minutes could be useful for other addictive 
states such as addictive gambling and alcohol 
dependence in situations where clinical trials 
of longer acting mu receptor antagonists have 
been less efficacious [130].
Zolmitriptan is a selective serotonin 5-HT1B 
receptor agonist that can be delivered orally or 
intranasally for the treatment of migraine head-
aches [129]. When delivered intranasally, the 
onset of action is detectable within 10 minutes 
and can quickly abolish major migraine symp-
toms [130]. Drug biodistribution studies in the 
nasopharynx, brain, lung, and abdomen were 
conducted using PET following IN administra-
tion of 11C labelled zolmitriptan (11C-zolmitrip- 
tan) [131]. In phase 1, the group determined 
the most appropriate times for PET scanning, 
whereas in phase 2, they validated the distribu-
tion, pharmacokinetics, and tolerability of 
11C-zolmitriptan. Healthy volunteers, aged 18- 
28 years, were scanned over sectors covering 
Figure 6. 11C-Carfentanil PET imaging of the brain following intranasal naloxone at 0-60 min or 300-600 min. (Adapt-
ed from Johansson et al., 2019). ROI-based binding potential was determined using PET imaging of 11C-Carfentanil 
superimposed on a brain MRI template without naloxone administration (upper left image), at 0-60 min following 4 
mg of naloxone (upper second image from left), at 0-60 min following 2 mg naloxone (upper third image from left), 
or at 300-360 min following 2 or 4 mg naloxone. The bottom row indicates percent occupancy of naloxone relative 
to placebo at the doses administered in the upper row. BPND is the binding potential of [
11C] carfentanil relative to 
the uptake of the tracer in the non-displaceable compartment.
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one of the nasopharynx, brain, lungs or abdo-
men for up to 1.5 hours post dose by PET. It 
was determined that most of the 11C-zolmitrip- 
tan was detected in the nasopharynx immedi-
ately after IN administration. Moreover, that 
was a detectable radioactivity within brain tis-
sue, thereby suggesting central penetration of 
the drug [131].
Single-photon emission computed tomography
SPECT is a nuclear tomographic imaging tech-
nique that depicts the distribution of gamma-
ray-emitting radionuclides (e.g., technetium-99 
(99mTc), thallium-201 (201TI), 123I, and 131I), acquir-
ing planar (projection) images from multiple 
angles. These projection images are combined 
to reconstruct a 3D image depicting the distri-
bution of radionuclides in patients. It depends 
on radiopharmaceuticals labelled with radio- 
nuclides whose radioactive decay produces 
gamma photons directly. 99mTc serves as the 
workhorse for PET imaging and is the most 
common radionuclide used due to its short 
half-life [132]. The most common method of 
performing SPECT is with a rotating gamma 
camera mounted on a special gantry that 
allows up to 360-degree rotation around the 
patient so that photons are captured in multi-
ple directions. Some recent SPECT systems 
employ more than one gamma camera head, 
reducing scan time. In single-head SPECT sys-
tems, the gamma camera is rotated either 180 
degrees (for most cardiac imaging applica- 
tions) or 360 degrees (for most non-cardiac 
imaging applications) so that a standard pro- 
jection (planar) image is acquired at each angle. 
Transverse images are reconstructed from 
the projection data on the system’s computer 
[92]. Like PET, SPECT allows for the freedom 
to work with other modalities like CT or MRI. 
Additionally, SPECT scans are far less expen-
sive than PET scans (Table 1). However, SPECT 
is less quantitative than PET. It is also less sen-
sitive than PET because it requires physical col-
limators that reject photons that are not within 
a very limited angular range. The collimation 
requirement in SPECT also introduces noise 
and increases san time.
At the preclinical level, Esposito et al. tested a 
99mTc-labeled nanostructured lipid carrier (NLC) 
(based on a tri-block copolymer platform) di- 
stribution using SPECT following IN, intraperito-
neal, IV and oral administration in a Wistar rat 
model as a potential therapeutic application for 
obesity or other metabolic disorders [133]. The 
in vivo study demonstrated stability of the 
NLCs, indicating suitability of the system to 
carry both drugs and radiotracers for both ther-
apeutic and diagnostic applications. Activity 
was visualized in the nasal cavity but not in the 
brain [133]. In addition, Mandlik et al. used 
99mTc-labelled, zolmitriptan-loaded nanocarri-
ers for in vivo analysis of efficient drug target-
ing, biodistribution, and kinetics for the treat-
ment of migraines [134]. The anti-migraine zol-
mitriptan-loaded into radiolabeled nanostruc-
tured polymeric carriers and delivered intrana-
sally to Swiss albino mice. The 99mTc radiola-
belled nanocarriers were efficient in targeting 
the brain, resulting in higher zolmitriptan-load-
ed concentrations compared to intranassally 
delivered unencapsulated free drug solution 
(i.e., 99mTc-zolmitriptan) and intravenously deliv-
ered 99mTc-labelled, zolmitriptan-loaded nano-
carriers. The authors were able to monitor the 
biodistribution of each therapy by a cou- 
pled bimodal SPECT-CT system. Due to the 
increased radioactivity found in the brain from 
analysis of the scintigrams and pharmacoki-
netic parameters, attesting to a more superior 
drug targeting, it was concluded that intrana-
sally delivered zolmitriptan-loaded nanocarri-
ers are a much more promising system than 
free drug solution or intravenously delivered 
drug-loaded nanocarriers.
There are very few available studies specifi- 
cally utilizing SPECT to study IN delivery in 
humans. In one study, the clinically approved 
radiotracer thallium-201 (201TI) was adminis-
tered intranasally in 24 humans in an attempt 
to visualize the nose-to-brain route using 
SPECT/CT fused with MR images of the same 
subjects [135]. 201TI was visualized in the olfac-
tory bulb at 24 hours following IN delivery 
through the anterior skull base via the cribri-
form lamina. More recently, olfactory bulb 
uptake of 201TI was demonstrated in healthy 
human subjects following IN delivery. This was 
significantly lower in anosmic patients [136] 
(Figure 7). SPECT/MRI with nasal 201TI is a dual-
modality technique that can be used to assess 
the olfactory nerve function [136]. In another 
study, SPECT/MRI was used 24 hours post 201TI 
injection to assess the olfactory nerve connec-
tivity in post-traumatic patients. There was a 
significant decrease of 201TI detection in olfac-
tory-impaired patients [136].
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Gamma scintigraphy
Gamma scintigraphy is a nuclear medicine 
imaging approach that uses the same gamma-
emitting radiotracers used in SPECT such as 
99mTc and 201Tl. The drug-labelled radionuclide 
(i.e., radiopharmaceutical) emits gamma rays 
from the organ/tissue where it is localized; 
these rays are detected by external gamma 
cameras, forming a 2D projection image which 
depicts the biodistribution of the gamma-emit-
ting source in the body. Gamma scinitigraphy is 
often used as an in vivo IN imaging technique 
preclinically because it is readily available, fast, 
and inexpensive (Table 1). However, some 
drawbacks include its ability to only produce 
2D/planar images, relatively poor spatial reso-
lution compared to MRI or CT, lower detection 
sensitivity than PET or SPECT, and the deposi-
tion of radiation dose.
bypassing the BBB. This study, too, suffered 
from the lack of verifiable anatomic localization 
since the nasal cavity cannot be delineated 
from the brain in these images using planar 
imaging alone.
One key component to efficient nose-to-brain 
delivery in humans is the development of a 
nasal drug delivery device that facilitates focal 
deposition of the drug onto the dorsal nasal 
epithelium. Various companies market this abil-
ity using various technologies, including bidi-
rectional technology (OptinoseTM) [141], con-
trolled particle dispersion technology (Kurve 
Technology) and Precision Olfactory Delivery 
(POD) technology (Impel Neuropharma) [142]. 
As an illustration, Optinose developed a breath-
powered device with a nasal piece that extends 
beyond the nasal valve in the nasal cavity. In 
one study, gamma scintigraphy images were 
Figure 7. SPECT-MR imaging of 201thallium following intranasal delivery in a 
human (adapted from Shiga et al., 2013 with permission). Representative 
SPECT images acquired 24 hours after unilateral intranasal delivery of 201Tl 
in 10 healthy volunteers and 21 patients with olfactory dysfunction from 
various causes. The SPECT images were fused with MRI images from the 
same patients. 201Tl was shown to migrate to the olfactory bulb (white ar-
rows) which was significantly correlated with odor recognition thresholds 
and volume of the olfactory bulb on MRI.
Recently, ropinerole-loaded 
mucoadhesive NPs [137], 
lorazepam-loaded PLGA NPs 
[138], and risperidone-loaded 
solid lipid NPs [139], labeled 
with 99mTc, demonstrated gr- 
eater brain concentrations 
after IN delivery compared to 
IV delivery. In a proof-of-con-
cept study, Kakkar et al. 
reported that circumin-loaded 
lipid NPs could be visualized 
in a New Zealand rabbit bra- 
in at 4 hours following IN de- 
livery using gamma scintigra-
phy, but was not visualized in 
the brain following IV delivery 
[140]. Unfortunately, the imag-
es provided show only a dor- 
sal view without correlational, 
cross-sectional imaging to dis-
tinguish between signals in 
the nasal cavity versus signal 
in the brain. Gamma scintigra-
phy in rats was performed 
following IN administration of 
ropinerole hydrochloride-load-
ed chitosan NPs to ascertain 
the localization of drug in the 
brain following IN administra-
tion of formulations [137]. The 
brain-to-blood ratios obtained 
at 30 minutes are indicative of 
direct nose-to-brain transport, 
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obtained 2 minutes after the delivery of a tradi-
tional spray using an Optinose breath-powered 
device (Figure 8) [142]. Images were superim-
posed on a lateral MRI image. The Optinose 
breath-powdered device was superior for dem-
onstrating a broader deposition on ciliated 
respiratory epithelium in the nasal cavity, espe-
cially in the upper and middle posterior regions. 
There was less deposition in non-ciliated nasal 
regions, which are thought to be less important 
in nasal drug delivery.
Computed tomography
Computed tomography has had a limited role in 
nose-to-brain drug delivery largely because of 
its lower soft tissue contrast and lower sensitiv-
ity of detection compared to MRI and nuclear 
medicine, respectively. However, CT has been 
useful in characterizing the nasal anatomy and 
dynamic airflow in small animals and humans, 
which are important for testing IN delivery 
methods [143]. CT utilizes x-rays to generate 
cross-sectional, gray-scale images with various 
pixel (or voxel) intensity values Hounsfield Units 
(HU) [144]. The degree to which soft tissues 
attenuate x-ray photons and prohibit them from 
reaching the detectors determines the image 
characteristics [145]. CT is widely available, 
relatively inexpensive, and its images can be 
acquired quickly compared to other imaging 
modalities such as MRI (Table 1). However, the 
use of CT involves ionizing radiation, which has 
combination of high-resolution, static micro-CT 
scans with dynamic micro-CT scans was used 
to assess the deposition patterns of inhaled 
particles for obligate nose breathers like the rat 
[146]. In another study, three-dimensional CT 
was used to study the to pography of the nasal 
and paranasal sinuses, which were compared 
with corrosion casting and gross and histologic 
cross-sections [147]. In humans, Warnken et 
al. utilized CT to create an anatomical 3D- 
printed model of the nasal cavity for both pedi-
atric and adult patients to evaluate the deposi-
tion pattern of several IN agents [148]. CT was 
also used for an in vitro model of the nasal cav-
ity to determine the penetration of a nasal 
spray or the deposition of the olfactory nerve 
[149, 150]. Furthermore, Shang et al. used CT 
to reconstruct a human nasal cavity model to 
better understand mucociliary clearance by 
examining mucus flow patterns [151]. Often, as 
mentioned earlier, CT is used in conjunction 
with other modalities to gain a better under-
standing of the intra-nasal delivery. In fact, CT 
can be used for anatomic correlation when 
combined with PET or SPECT since these 
modalities have inherently poor anatomic spa-
tial resolution. CT also allows attenuation cor-
rection, reducing attenuation artifacts and 
enabling an improvement in the overall diag-
nostic performance greater than either modali-
ty alone [92].
Figure 8. Gamma scintigraphy of an example of a breath-powered na-
sal spray. (Figure included with permission from Djupesland et al., 2013.) 
Gamma camera images 2 minutes after delivery using a traditional liquid 
spray (A) and powder with OptiNose Breath-Powered Device (B) shown with 
a logrithmic hot iron intensity scale. Initial gamma images from one of the 
subjects are esuperimposed on a lateral MR image. The red dotted lines 
indicate the segmentation used for regional quantification.
the potential for deterministic 
and stochastic side effects 
to patients [144, 145], making 
it not recommended for pre- 
gnant women. Also, patients 
may experience adverse reac-
tions to its iodine- and barium-
based contrast agents.
While CT has not been utili- 
zed as a standalone imaging 
modality for IN delivery, it has 
indeed been used as an ad- 
junct anatomical modality al- 
ong with dynamic imaging su- 
ch as PET [123] and SPECT 
[134]. Furthermore, in ani-
mals, the upper and lower air-
way morphology in Sprague-
Dawley rats was studied using 
micro-CT and image segmen-
tation techniques [146]. The 
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Optical imaging
Optical imaging techniques, particularly BLI 
and FLI, provide in vivo information at the pre-
clinical level on disease (e.g., tumor) progres-
sion [152] and treatment biodistribution [152, 
153]. Both BLI and FLI quantify light production 
for spatial and anatomical information during 
real-time studies through individual processes 
[154]. BLI relies on an enzymatic reaction as 
chemical energy converts into light energy with-
out an excitation source [155]. The complete 
reaction uses luciferase genes in the presence 
of a substrate, an energy source and oxygen 
[154]. Substrates include an endogenous 
reduced riboflavin phosphate (FMNH2) and 
long-chain aliphatic aldehyde or exogenous co- 
elenterazine and D-luciferin [152, 154], which 
can be combined with luciferases such as 
Gaussia princeps luciferase (Gluc) [152, 155] 
or firefly luciferase (Fluc) [59, 156]. Because of 
newer cloning and transfection techniques, 
genes coding for the enzyme and substrate can 
be introduced into cells for imaging [157]. For 
example, inserting the lux operon into a plas-
mid or chromosome catalyzes the aldehyde 
substrate and can be monitored at a wave-
length of 490 nm [154]. The absence of 
required external light makes BLI very favor-
able since there is a unidirectional full conver-
sion from chemical energy to light [155]. BLI 
avoids toxic contrast agents, ionizing radiation, 
high cost, and low throughput associated with 
other techniques such as MRI or CT [157]. 
Other advantages include ease of use and 
little to no background signal except in the 
abdomen from digested rodent chow-contain-
ing chlorophyll [154]. Multiple animals can be 
imaged at once in a single view, which reduces 
costs and imaging operation time, and the non-
invasiveness of the procedure allows for serial 
in vivo imaging [157]. A major limitation of BLI, 
however, is that luciferases often do not permit 
deep-tissue imaging greater than 1-2 cm [154, 
155]. This limitation generally prevents optical 
imaging from being useful in clinical applica-
tions where deeper tissue penetration is a 
requirement. While optical imaging is one of 
the most sensitive imaging modalities, im- 
proved sensitivity needs to come from imaging 
advancements as well as modified substrates 
(Table 1). For example, NanoLuc is meant to 
have improved stability as well as increased 
luminescence; however, its interaction with 
mammalian tissues currently challenges its 
use. One group utilized red-shifted luciferins 
designed based on the combination of syn- 
thetic coelentarazine analogs and NanoLuc 
mutants to improve such sensitivity [158, 159]. 
BLI is strongly dependent on substrate admin-
istration and, therefore, timing and bioavailabil-
ity are two important factors [154]. If certain 
animals require different administration times, 
cost could become quite expensive. Finally, 
substrate administration is often via tail vein 
injection which often requires experienced indi-
viduals and could pose a challenge to experi-
ments, especially when working with smaller 
animals such as mice, if the injection is not 
done correctly.
In a preclinical model, Fuentes et al. used BLI 
in order to track the distribution of oncolytic 
virus-loaded NSCs in the presence of methima-
zole of fibrin glue as a potential treatment 
option for glioblastoma [59]. Methimazole and 
fibrin glue were used to enhance penetration of 
the olfactory epithelium. NSCs were overex-
pressed with chemokine receptor type 4 to also 
facilitate travel to the brain and were modified 
to be Fluc-expressing for BLI. The cells were 
administered intranasally and D-luciferin sodi-
um salt was injected intraperitoneally and 
placed inside each nostril. Figure 9 represents 
increased brain localization of NSCs in the 
presence of methimazole at different time 
points compared to saline and fibrin glue [59]. 
In both the saline and the fibrin glue groups, it 
is clear the NSCs either cleared or remained in 
the nasal cavity. Figure 9 has been chosen as a 
representative BLI image because of its sharp 
resolution and its change longitudinally. BLI 
images of the brain are often challenging to 
acquire in mouse models as it is challenging to 
discern between the nasal cavity and brain. 
However, here as time continues, the region of 
interest shrinks and becomes more concentrat-
ed at the brain and this evident shift discerns 
between the two regions.
FLI is a two-step process as it requires an exter-
nal light with an appropriate wavelength to 
excite a fluorescent molecule (fluorophore). 
This fluorophore is excited to a higher energy 
state and as the molecule relaxes, light is emit-
ted at a different wavelength than the excita-
tion wavelength [154, 157]. There are a variety 
of proteins that can be used for FLI including 
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green fluorescent protein (GFP) [152, 160], 
Turbo red fluorescent protein (TurboRFP) [154], 
and mCherry fluorescent protein [152], in addi-
tion to metals such as gold [161]. Some advan-
tages of FLI include exquisite sensitivity and 
specificity, high temporal and spatial resolu-
tion, availability, easy to operate and inexpen-
sive (Table 1) [157]. FLI also does not involve 
ionizing radiation and is extremely fast in vivo, 
with measureable signal available within sec-
onds [154]. On the other hand, FLI has disad-
vantages such as a smaller limit of detection/
penetration depth of only a few millimeters 
compared to that of BLI and background auto-
fluorescence [154].
Fluorescent molecules can be conjugated to a 
wide variety of entities, including cells and NPs. 
For example, Bagheri-Mohammed et al. tag- 
ged human endometrium-derived stem cells 
(HEDSCs) with GFP for a possible treatment of 
Parkinson’s disease [160]. The HEDSCs were 
administered intranasally and ex vivo fluores-
cence imaging was performed. It was found 
that the HEDSCs were able to migrate to the 
substantia nigra pars compacta and behavior 
was improved [160]. Another group fluorescent-
ly labelled poly(N-vinyl pyrrolidone)-based na- 
nogels that were attached to insulin for the 
treatment of Alzheimer’s disease [47]. By fluo-
rescently labelling the nanogel, the group was 
able to monitor biodistribution and clearance 
and determine that the mucosa was not altered 
and brain activity was enhanced [47].
FLI and BLI can be used together to provide 
more information. In a very interesting study, 
Carvalho et al. used both FLI and BLI to mon- 
itor the distribution of olfactory ensheathing 
cells (OECs) and their role as a carrier for gene 
therapy in the treatment of glioblastoma [152]. 
OECs were modified to carry a fusion protein 
between cytosine deaminase and uracil phos-
phoribosyl transferase which converts the pro-
Figure 9. In vivo BLI after IN delivery of NSCs. (Figure adapted, with permission, from Spencer et al., 2019) Oncolytic, 
virus-loaded NSCs were intranasally delivered in the presence of either fibrin glue, methimazole, or saline. Their dis-
tribution was monitored over time using BLI. Methimazole best disrupts the olfactory epithelium to facilitate nose-
to-brain transition for the treatment of glioblastoma which is seen from the increased concentration and localized 
region of interest at the brain.
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drug 5-fluorocytosine into its cytotoxic me- 
tabolite. OECs and OECs labelled with the 
fusion protein were engineered to express 
Gluc, while glioblastoma stem cells were modi-
fied to express Fluc for an in vitro BLI study 
measuring viability using two separate sub-
strates, coelenterazine and D-luciferin, respec-
tively. An in vivo BLI study combined with an ex 
vivo FLI study using the same cell modifications 
showed a decrease in tumor size in the pres-
ence of labelled OECs and 5-fluorocytosine as 
well as migration of both OECs using the nasal 
pathway into the glioma site [152]. Briefly, mice 
were injected with glioma stem cells expressing 
Fluc and mCherry fluorescent protein and one 
week later were intranasally administered 
OECs and labelled OECs expressing Gluc and 
GFP. The mice were then treated daily with an 
intraperitoneal injection of 5-fluorocytosine. 
D-luciferin was injected intraperitoneally at 
150 µg per gram of body weight and imaged 
ten minutes later. The fluorescent proteins 
were utilized in an ex vivo FLI study to confirm 
migration to the primary tumor site [152].
Another special type of optical imaging, known 
as photoacoustic (PA) imaging, takes advan-
tage of short light pulses to excite a region of 
interest (i.e., absorbing medium), causing a 
slight temperature rise (in the millikelvin ran- 
ge) and thermoelastic expansion [162]. Conse- 
quently, pressure waves emitted at ultrasonic 
frequencies are recorded by a diagnostic 
ultrasound transducer that produces a 3D 
image of the absorbing medium distribution. 
Compared to traditional optical imaging, this 
imaging approach provides deeper tissue pen-
etration (up to 5-6 cm) and offers higher resolu-
tion due to the weaker tissue scattering of 
ultrasound waves [162]. By virtue of its capabil-
ity in visualizing the optical absorption proper-
ties of biologic tissues, PA imaging also pro-
vides higher tissue contrast than conventional 
ultrasound imaging (Table 1) [163]. Additionally, 
PA imaging utilizes a nonionizing electromag-
netic radiation, similar to BLI and FLI.
Near-infrared (NIR, 650-900 nm) absorptive 
materials are used as contrast agents to 
improve PA imaging sensitivity and tissue pen-
etration results [164]. Some studies have used 
PA with NIR NPs for contrast enhancement, 
tumor targeting, or multimodal imaging [164]. 
One study, particularly, incorporated a gold 
nanorod (GNR) into porous magnetic nanosh- 
ells [165]. The highly preserved plasmonic fea-
ture of GNRs enabled photothermal-induced 
PA imaging. Doxorubicin, as a model antican- 
cer drug, was loaded into GNR nanocapsules 
and, under the guidance of MRI/PA dual-modal 
imaging and magnetic tumor targeting, a photo-
thermal-chemo synergistic therapy was con-
ducted via NIR laser for a highly efficient tumor 
eradication. It was shown by H&E stained imag-
es, blood parameters, and the bodyweight of 
treated groups that the NPs were well tolerated 
[165]; however, the nonbiodegradability and 
potential long-term toxicity of these nanomate-
rials impact their clinical translation. Data 
regarding PA-assisted IN drug delivery remain 
to be explored.
Conclusions, perspectives and future direc-
tions
IN delivery to the brain can be evaluated with in 
vivo imaging to determine the fate of agents 
administered through this route and to assess 
the progression of diseases as well as the 
effectiveness of therapeutics. Various in vivo 
imaging techniques have been discussed in 
this review, highlighting the critical role imaging 
plays in the assessment of treatment efficacy. 
This review also discussed the nose-to-brain 
route as well as preclinical and clinical IN thera-
pies including small molecules, macromolecu-
lar agents, nanosystems, cellular therapies and 
theranostics.
Innovative IN therapies are continuously being 
developed. Therefore, we believe that there will 
be an increasingly growing interest and devot-
ed efforts to not only optimize current imaging 
methodologies but also develop new diagnostic 
capabilities in order to facilitate the discovery 
and clinical translation of novel IN therapies to 
the brain. In particular, molecular and multi-
modality imaging techniques will likely con- 
tinue to be at the forefront of development, 
dominating the aforementioned efforts. PET/
MRI, for instance, is an emerging molecular 
imaging modality that harnesses the strengths 
of both PET and MRI to produce hybrid quanti-
tative images with exquisite soft tissue con-
trast. Therefore, we believe, PET/MRI in IN 
delivery studies is and will continue to be a 
promising area of research and investigation 
with a potentially significant clinical impact in 
the future.
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In addition to optimizing and developing imag-
ing capabilities to facilitate IN delivery, future 
work should investigate strategies that enhance 
the delivery of drugs across the nasal barriers 
providing a more localized delivery to specific 
brain sites. One of these strategies is focused 
ultrasound (FUS), which is a noninvasive, thera-
peutic modality that harnesses the mechani- 
cal and thermal effects of ultrasonic beams 
focused at a region of interest in order to induce 
therapeutic benefits in deep-seated tissues 
with little or no harm to intervening tissues. 
FUS, which is FDA approved for certain clinical 
conditions, has already demonstrated promis-
ing initial results supporting its capability in 
enhancing the efficacy of IN delivery within 
targeted brain regions [166, 167]. The FUS-
mediated transport enhancement of intrana-
sally administered agents utilizes another FDA-
approved component, namely microbubbles, in 
order to induce mechanical effects (cavitation) 
that facilitate the transport of therapeutics in 
the brain.
We also believe that combination therapy, deliv-
ered intranasally using a NP-based drug deliv-
ery system, can bring about significant advan-
tages in treating debilitating brain diseases 
over single-drug therapies. Moreover, engineer-
ing multifunctional NP-based delivery systems 
that not only incorporate multiple anticancer 
drugs but also imaging agents as well as target-
ing moieties would certainly provide added 
advantages in IN delivery. Such a nanother-
anostic platform can enable targeted, image-
guided IN delivery to the brain, utilizing one or 
more of the diagnostic imaging modalities dis-
cussed in this review for treatment planning, 
real-time monitoring and control, as well as 
posttreatment evaluation of efficacy.
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Introduction: Glioblastoma (GBM) is a lethal brain tumor with a poor prognosis. GBM inevitably recurs 
in part due to cancer-derived stem cells (CSC) resistant to temozolomide (TMZ), which is the drug of 
choice for first-line therapy, and radiation therapy. CSCs regenerate rapidly and overexpress a 
methyltransferase which overrides the DNA alkylating mechanism of TMZ, leading to drug resistance. 
Multifunctional nanosystems can both target tumor and transport combination therapies to the tumor 
bed. Idasanutlin (RG7388, RO5503781) is a potent, selective small molecule and MDM2 antagonist that 
synergistically kills GBM cells when combined with TMZ (1). We developed a multifunctional hybrid 
polymer micellar nanoparticle containing TMZ and RG7388 that could target the CD133 antigen 
expressed on the surface of a GBM CSC subpopulation through covalent bonding of an aptamer derived 
based on the functional site of CD133 antibody (2). 
Methods: A nanoparticle encapsulating both TMZ and RG7388 comprised of poly(lactide-co-glycolide) 
(PLGA) and polystyrene-b-polyethylene oxide (PS-b-PEO) using a modified double emulsification solvent 
evaporation method. PLGA and PS-b-PEO were combined to form a polymer micellar nanoparticle for 
size reduction (3). An ester-PLGA conjugate was used to permit covalent bonding of a CD133 aptamer. 
Size, surface charge, drug-loading efficiency and morphology were characterized in vitro using dynamic 
light scattering, UV-Vis spectroscopy and transmission electron microscopy. Human-derived cancer stem 
cells were grown in culture and were treated with TMZ and RG7388 or nanoparticles containing both 
compounds. 
Results: The mean size of the TMZ + RG7388-loaded nanoparticles was 88 nm with a polydispersity 
index of 0.15. The mean nanoparticle charge was -9 mV with spherical morphology. Encapsulation 
efficiency of 14% for nanoparticles loaded with TMZ only was higher than the traditionally reported 2% 
in the literature. Preliminary conjugation efficiency studies revealed a 96% aptamer binding confirmed 
by fluorescent analysis. TMZ and RG7388 achieved 50% cell killing at 268 µM and 12 µM, respectively. 
Preliminary studies of CSCs treated with TMZ and RG7388 nanoparticles seem to produce a dose 
response curve. Studies of combination therapy with and without NPs and aptamer are ongoing.  
Conclusion: A multifunctional nanosystem containing two potent chemotherapeutic drugs targeted to 
the GBM stem cell subpopulation with a CD133 aptamer was synthesized and evaluated in vitro.  
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Learning Objectives:  
• Understand the need for novel therapies for the treatment of glioblastoma 
• Differentiate the principles behind single and double emulsion techniques and when they should 
be applied  
• Discuss the various measurement techniques utilized in developing a multi-functional 
nanocarrier 
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• Delivery vehicle – Nanoparticle/nanomaterial 
• Delivery vehicle – Targeted  
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Figures:  
 
 
 
 
 
 
 
 
 
Figure 1: Representative dynamic light scattering measurement of the hydrodynamic distributions of 
TMZ-loaded nanoparticles (left), and TMZ+RG7388 nanoparticles (right).  
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Figure 3: Cytotoxicity tests in GBM cancer stem cells with TMZ treatment (top left), RG7388 treatment (top 
right), and TMZ+RG7388-loaded nanoparticle treatment (bottom).   
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Figure 2: Representative morphology by transmission electron microscopy of TMZ-
loaded nanoparticles (left), and TMZ+RG7388 nanoparticles (right).  
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